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Abstract
Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative
regulator of neuron and oligodendrocyte survival, neurite extension, axon regeneration,
oligodendrocyte differentiation, axonal myelination and functional recovery; all processes highly
implicated in numerous brain-related functions. Although playing a major role in developmental brain
functions, the potential application of Lingo-1 as a therapeutic target for the treatment of neurological
disorders has so far been under-estimated. A number of preclinical studies have shown that various
methods of antagonizing Lingo-1 results in neuronal and oligodendroglial survival, axonal growth and
remyelination; however to date literature has only detailed applications of Lingo-1 targeted
therapeutics with a focus primarily on myelination disorders such as multiple sclerosis and spinal cord
injury; omitting important information regarding Lingo-1 signaling co-factors. Here, we provide for
the first time a complete and thorough review of the implications of Lingo-1 signaling in a wide range
of neurological and psychiatric disorders, and critically examine its potential as a novel therapeutic
target for these disorders.

Key Words: Lingo-1 signaling; gene expression; neurological pathologies; psychiatric disorders;
therapeutic strategies
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1. Introduction
Myelination is a fundamental progressive process occurring throughout the brain from embryonic
stages of development through to adolescence. During the last decade, novel signaling pathways,
largely involving myelin associated inhibitory proteins including: myelin associated glycoprotein
(MAG), oligodendrocyte-myelin glycoprotein (OMgp) and neurite outgrowth inhibitor (Nogo) were
found to inhibit the growth of neurons and myelination. Mechanisms involved in these processes
largely implicate a receptor complex comprised of the p75 neurotrophin receptor and the (then) newly
discovered Nogo Receptor (NgR) (Caroni and Schwab, 1988; Chen et al., 2000; Domeniconi et al.,
2002; Fournier et al., 2001; GrandPré et al., 2000; Liu et al., 2002; Kevin C. Wang et al., 2002a,
2002b). The mechanism by which NgR regulates axonal growth is initiated by the high affinity
binding of Nogo to the NgR, however the NgR itself does not contain a transmembrane domain and as
such requires a transmembrane co-receptor in order to elicit intracellular signals. While p75 has been
shown to elicit the transduction of inhibitory NgR signals (Kevin C. Wang et al., 2002a), certain NgR
containing cell types not expressing p75, were still found to be able to transduce inhibitory NgR
signals (Kevin C. Wang et al., 2002a), leading to the discovery of TNF receptor orphan Y (TROY) as
a functional homolog of p75 within the signaling complex (Shao et al., 2005). The functional ternary
receptor complex was suggested to be complete when a third co-receptor was discovered in the form
of Lingo-1 (Leucine-rich repeat and Ig domain-containing, Nogo receptor-interacting protein) (Mi et
al., 2004) and the Lingo-1/NgR/p75 or TROY complex was born.
Lingo-1 was first identified as LERN1 (leucine-rich repeat neuronal protein 1), a transmembrane
leucine-rich protein coded for by the novel gene LRRN6A discovered by Carim-Todd and
collaborators (Carim-Todd et al., 2003) on human chromosome 15q24-26 just over a decade ago. It
was suggested that due to the developmental expression profile of LRRN6A, the predicted protein
structure of LERN1 and its similarity to proteins already identified as having a vital role in nervous
system development and maintenance, that the LRRN6A gene and LERN1 protein would be highly
relevant for further study in neurobiology. While a number of previously uncharacterized central
nervous system-specific proteins were being assessed for their ability to bind to NgR, Lingo-1 was
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discovered as we know it today, Leucine-rich repeat and Ig domain-containing, Nogo receptorinteracting protein (Mi et al., 2004). Lingo-1 has been widely studied in relation to multiple sclerosis
and spinal cord injury due to its prominent role in myelination and myelin related processes, however
there has always been lack of information in relation to psychiatric disorders. Considering the ever
growing evidence that the essential developmental functions of neurite outgrowth and myelination are
disrupted in psychiatric disorders like schizophrenia, it seems timely and topical to consider the role
of Lingo-1 in neuropsychiatric disorders. Here we provide a comprehensive review on Lingo-1, a
relatively new candidate that since discovery has been studied across a wide range of neurological
disorders, and why it is a promising candidate for future research in neuropsychiatric disorders and
their therapeutic approaches.
Note: For the purpose of this review, the terms LRRN6A and LERN1 will no longer be used and the
gene and protein will be referred to as Lingo-1 and Lingo-1 respectively.
2. Lingo-1: the Gene, Structure, Expression and Function
The identification and characterization of the Lingo-1 gene (Carim-Todd et al., 2003) was an
important first step to uncovering the function of Lingo-1. The Lingo-1 locus on human chromosome
15q24-26 is a region that has been widely implicated in a number of psychiatric, addictive and anxiety
related disorders, and genomic alterations in this chromosomic region are considered to be
susceptibility factors for schizophrenia, depression, autism, panic disorders, anxiety and phobic
disorders (Gratacòs et al., 2001; McInnes et al., 2010).
The Lingo-1 gene maintains a very high degree of conservation across a large number of unrelated
vertebrate species, including both mouse and rat (Carim-Todd et al., 2003). Furthermore, two
additional paralogous genes have been mapped to human chromosomes 9 and 19 which were
identified as LRRN6B and LRRN6C, coding for proteins LERN2 and LERN3 (Carim-Todd et al.,
2003) also known as Lingo-3 and Lingo-2 respectively (Chen et al., 2006).
The Lingo-1 structure has been shown to be highly stable in a tetrameric conformation in both its
crystal form and in solution, facilitated by its leucine-rich repeat-Ig-composite fold (Mosyak et al.,
4

2006). Due to the tetramer burying such a large surface area into the cell membrane it is thought that
this may in fact serve as an efficient and stable scaffold for a binding platform, facilitating the
assembly of the Lingo-1/NgR/p75 or TROY complex, localizing signaling functions to the sites of
neuronal pathways that terminate axon growth (Mosyak et al., 2006). Accordingly, knowing that
Lingo-1 forms tetramers may provide an answer to the still unresolved questions about the
stoichiometry of the Lingo-1/NgR/p75 or TROY receptor complex. It has been hypothesized that
Lingo-1 may form tetramers relative to the monomers on the cell surface, meaning that each signaling
complex may consist of four of each receptor component (4:4:4) rather than one (1:1:1) as previously
thought. It is apparent that Lingo-1 is involved in a number of central nervous system processes, in
addition to having the ability to bind a number of signaling molecules, thus its functional roles within
the central nervous system and its mechanisms of oligomerization may vary depending on the where
and when it is expressed (Mosyak et al., 2006). Just recently the crystalline tetrameric formation of
Lingo-1 has been confirmed by Pepinsky et. al., in addition to showing for the first time that Lingo-1
is also present as a tetramer on cells expressing full-length Lingo-1 (Pepinsky et al., 2014). This
tetrameric formation on transfected cells is indicative of oligomer formation being an intrinsic
property of Lingo-1 in the absence of its ligands or co-receptors (Pepinsky et al., 2014).
Proteins containing leucine-rich repeats have been shown to play an important role in protein-protein
interactions (Kajava et al., 1995; Kobe and Deisenhofer, 1994; Kobe and Kajava, 2001) in a wide
variety of cellular processes (Carim-Todd et al., 2003) including ligand recognition (Brose et al.,
1999; Chen et al., 2001; Li et al., 1999; Vourc’h et al., 2003; Kevin C. Wang et al., 2002b). Their
implication in important neurodevelopmental functions such as neuronal differentiation and growth
(Halegoua et al., 1991) and the regulation of axon guidance, axon branching, cell-migration and
regeneration processes (Bormann et al., 1999; Brose and Tessier-Lavigne, 2000; Ishii et al., 1996;
Nguyen-Ba-Charvet and Chédotal, 2002), results consequently in their involvement in neurological
diseases such as hereditary epilepsy and X-linked stationary night blindness (Bech-Hansen et al.,
2000; Kalachikov et al., 2002; Morante-Redolat et al., 2002; Pusch et al., 2000). Since Lingo-1 is a
leucine rich repeat protein, and considering its genetic locus is in a chromosomic region associated
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with a high risk for a number of psychiatric disorders, Lingo-1 makes for an ideal candidate for study
in a vast array of neurological disorders.
Within the healthy adult human brain Lingo-1 RNA expression was found to be abundantly and
almost exclusively expressed in the central nervous system (Carim-Todd et al., 2003). A closer look at
the distribution of Lingo-1 across the adult human brain showed that expression was highest in the
cerebral cortex (Carim-Todd et al., 2003), a region heavily involved in sensory-motor function,
cognition and working memory; the hippocampus (Carim-Todd et al., 2003), responsible for long
term memory and the encoding and retrieval of multi-sensory information; the amygdala (Carim-Todd
et al., 2003), a region highly implicated in the stress response (Stork and Pape, 2002), as well as the
thalamus; with a more constant and basal level of expression across the remainder of the brain
(Carim-Todd et al., 2003). In the context of neurological and psychiatric disorders, these brain regions
that have been identified as highly expressing Lingo-1 transcripts, have also been heavily implicated
in neuropsychological disorders such as stress and panic disorders (Stork and Pape, 2002),
Parkinson’s Disease (Inoue et al., 2007) and Alzheimer’s Disease (Zhu et al., 2007), as well as
schizophrenia (Fung et al., 2010), temporal lobe epilepsy (Goffin et al., 2011) and amnesia (Jarrard,
2001), thus potentially implicating Lingo-1 in a wide variety of central nervous system disorders.
To confirm the findings of a differential expression pattern of Lingo-1 across the adult human brain,
and due to the high degree of identity (99.5%) between human and mouse orthologs of Lingo-1, levels
of Lingo-1 mRNA have been examined in both the adult mouse brain (Carim-Todd et al., 2003), as
well as across different stages of neurodevelopment from embryonic stages to adulthood in both the
mouse (Carim-Todd et al., 2003) and the rat (Mi et al., 2004). Both mouse and rat results confirmed
first of all that the expression of Lingo-1 is highly specific and is confined to the adult central nervous
system. Similarly, the highest levels of expression were again found in the neocortex (Carim-Todd et
al., 2003; Mi et al., 2004), hippocampus, thalamus and amygdala, in addition to the entorhinal cortex
and various other components of the limbic system (Carim-Todd et al., 2003). While Lingo-1 is a
highly expressed central nervous system transcript in the adult human, rat and mouse brain, it is
ubiquitously expressed in the embryonic mouse up until embryonic day E7.5 (Carim-Todd et al.,
6

2003). By E17.5 Lingo-1 is expressed exclusively within the central nervous system with the highest
levels detectable within the neocortex, hippocampus, piriform cortex, and amygdala (Carim-Todd et
al., 2003) corresponding to similar regions that presented with the highest expression levels in the
adult mouse, rat and human, thus demonstrating that Lingo-1 is likely to have a highly conserved
function throughout development across a variety of mammalian species.
Neuronal sprouting and myelination are developmental milestones and are an integral part of
neurodevelopment. Furthermore, Lingo-1 has been shown to be expressed early in embryonic
development as described above. Accordingly in normal brain development, Lingo-1 is a potent
negative regulator of myelination and neurite outgrowth, both of which are key neurodevelopmental
processes. Lingo-1 was also reported to be expressed on oligodendrocytes where it plays an important
role in the inhibition of oligodendrocyte differentiation and axon myelination (Mi et al., 2005).
Myelination was shown to be inhibited by endogenous Lingo-1 and antagonism of Lingo-1 was able
to reverse this inhibition (Mi et al., 2005). In support of these findings, electron microscope studies
have shown increased numbers of myelinated axons within the spinal cord of Lingo-1 knockout mice
compared to their wild type littermates (Mi et al., 2007, 2005). In contrast, transgenic mice
overexpressing Lingo-1 show a delayed onset of myelination (X. Lee et al., 2007). A study by Mi et
al. not only showed that Lingo-1 interacts with both NgR and p75, as a part of the receptor complex,
but also proved that it is capable of activating ras homolog gene family member A (RhoA), a small
GTP-binding protein, and mediating the activity of myelin inhibitors. The Lingo-1 cytoplasmic
domain was reported to be essential in providing the signal to activate RhoA, and thus to inhibit
axonal outgrowth and myelination (Mi et al., 2004). Without the intracellular domain of Lingo-1,
neurite outgrowth is restored in vitro, due to the interruption of the interaction between Lingo-1 and
its co-receptor binding partners (Mi et al., 2004).
3. Lingo-1 Signaling Pathways
In addition to the NgR/p75 or TROY co-receptors, Lingo-1 is able to interact with additional cofactors and/or co-receptors, leading to the activation of further downstream signaling pathways,
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resulting in the regulation of neuronal survival, axon regeneration, oligodendrocyte differentiation,
and myelination processes in the brain (Figure 1).
3.1. NgR/p75 or TROY Complex
NgR is encoded by the NgR gene (also known as RTN4R), located at locus 22q11.2 in humans, a
chromosomic region that has been previously identified as being involved in many psychiatric
disorders. A faulty NgR possibly caused by mutations within the gene itself, could result in abnormal
axonal connections. This hypothesis has caused much interest among researchers due to the large
number of neuropathologies that present with axonal abnormalities.
Studies have also shown that NgR plays a role in synaptic plasticity (Budel, 2007; Josephson et al.,
2003; McGee and Strittmatter, 2003; Trifunovski et al., 2004), thus it has been considered that any
aberrant enhancement of neuronal plasticity during neural development may be caused by a reduction
or complete loss of NgR function during the last phases of development (Budel, 2007; Budel et al.,
2008). Alteration of activity-driven synaptic plasticity at Schaffer collateral-CA1 synapses; and
abnormalities of dendritic spine shape have been previously observed in several animal studies,
notably including the use of NgR null mice (Lee et al., 2008; Raiker et al., 2010), suggesting a key
role of NgR in both of these processes.
NgR is expressed primarily on the axons of a subpopulation of neurons, including cerebral cortical
pyramidal neurons and cerebellar Purkinje cells (Kevin C Wang et al., 2002). In normal brain
development, oligodendrocytes are responsible for regulating axonal growth via the Nogo protein and
its receptor, NgR. Nogo binds to the leucine-rich repeat domains of NgR and facilitates the inhibition
of axon growth (Hu and Strittmatter, 2004). NgR is a 473-residue protein, anchored to the neuronal
membrane by a Glycosyl Phosphatydyl Inositol component. NgR protein is primarily comprised of a
leucine-rich repeat ectodomain domain (similar to the one of Lingo-1), capped by N-terminal and Cterminal cysteine rich molecules (He et al., 2003).
To our knowledge, levels of NgR protein expression in post-mortem tissue have only ever been
reported in the hippocampus in a cohort for Alzheimer’s Disease (Zhu et al., 2007). Interestingly,
8

NgR expression was increased in the hippocampus of patients suffering from Alzheimer’s Disease
suggesting that NgR may play a common role in a larger scope of brain disorders. The levels of
expression of the neurotrophin receptor p75, one of the direct binding partners involved in the
downstream signaling of NgR with Lingo-1 or TROY, was also found to be higher in post-mortem
brain tissue from Alzheimer’s Disease patients (Fujii and Kunugi, 2009), supporting the implication
of the NgR/p75 pathway in this disorder.
The Lingo-1 co-factor p75, is a well-defined member of the tumor necrosis factor receptor (TNFR)
superfamily and was originally identified as a low-affinity neurotrophin receptor (Rabizadeh and
Bredesen, 2003). The p75 gene is located at the human chromosomic region 17q21-22 and codes for a
427 amino acid residue protein (Lotta et al., 2014). p75 has a well-established role in the nervous
system, controlling the survival and differentiation of neurons (Dechant and Barde, 2002).
While selective knockdown of p75 in mice results in severe ataxia making detailed behavioural
testing near impossible (von Schack et al., 2001), it has been shown that interfering with the function
of the p75 receptor suppresses neurotrophin activity and results in schizophrenia related
endophenotypes (Rajakumar et al., 2004). p75 is a receptor for all mature and developing
neurotrophins (Barker, 2004). Considering the implication of brain-derived neurotrophic factor
(BDNF), the most widely studied neurotrophin and ligand for p75, with neurodegenerative and
neuropsychiatric diseases such as Alzheimer’s disease, depression and schizophrenia, it is reasonable
to consider that the neurotrophic receptor p75 itself, may play vital roles in the pathogenesis of a wide
variety of neurological disorders (Fujii and Kunugi, 2009). The loss of the p75 gene from neurons has
been shown to render them incapable of activating RhoA, subsequently inhibiting neurite outgrowth
in the presence of myelin inhibitors (Mi et al., 2004; Kevin C. Wang et al., 2002b), providing another
plausible link to a neurodevelopmental role in psychiatric disorders.
As part of the Lingo-1/NgR complex, the p75 neurotrophin receptor is specifically responsible for
transmitting intracellular signals. Certain neurons lacking p75 show neither RhoA activation, nor do
they exhibit neurite growth inhibition in the presence of myelin associated inhibitors, suggesting that
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p75 plays a significant role in the transduction of inhibitory NgR signals in vitro (Kevin C Wang et
al., 2002). On the other hand, some NgR containing cell types not expressing p75, have still been
found to transduce inhibitory NgR signals (Kevin C. Wang et al., 2002a), leading to the discovery of
TROY as a functional homolog of p75 within the signaling complex (Shao et al., 2005).
TROY is a type I membrane protein belonging to the same tumor necrosis factor subfamily as p75,
and is encoded by the TNFSF19 gene at human chromosome 13q12.11-12.3. Despite TROY
belonging to the same family as p75, unlike p75, TROY is widely expressed in adult neurons where it
can substitute for p75 in the Lingo-1/NgR/p75 signaling complex in the presence of myelin associated
inhibitors in neurons lacking p75 (Park et al., 2005; Shao et al., 2005). TROY is abundantly expressed
throughout neurodevelopment in neural stem cells located in the ventricular and subventricular zones,
and is also found to be more abundantly present throughout the adult central nervous system than its
homolog p75 (Hisaoka et al., 2003; Kojima et al., 2000; Park et al., 2005; Shao et al., 2005). TROY
and Lingo-1 are expressed together in subpopulations of reactive astrocytes, macrophages/microglia
and neurons, but not in oligodendrocytes (Satoh et al., 2007). Dominant-negative forms of p75 or
TROY, in addition to both p75 and TROY knockout mice, have reduced levels of activated RhoA and
enhanced neurite outgrowth in the presence of myelin inhibitors (Park et al., 2005; Shao et al., 2005;
Kevin C. Wang et al., 2002b).
Neurotropic growth factors are well known to regulate many aspects of neuronal development and
function (Huang and Reichardt, 2001; Segal, 2003). Lingo-1 can also interact with the complex
neurotrophin, nerve growth factor (NGF)/Trk receptor tyrosine kinase (RTK) TrkA, which leads to
the regulation of the expression of genes involved in oligodendrocyte differentiation and myelination,
such as oligodendrocyte transcription factor 2 (olig 2) and natural killer cell-associated antigen 2
homeobox 2 (nkx2.2) (Zhou et al., 2001).
The Lingo-1/NgR/p75 or TROY complex was the first cellular complex identified to determine the
functions of Lingo-1 in the brain. The characterization of the serine threonine kinase With No Lysine
K (WNK1) as both a modulator of the trimolecular receptor complex and as a direct downstream
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signaling partner of Lingo-1 has highlighted the importance and expansive nature of Lingo-1
functions in the brain.
3.2. WNK1
WNK1, a part of a distinct subfamily of serine threonine kinases implicated in the binding of ATP and
catalyzing phosphoryl transfer (Hanks et al., 1988), is expressed abundantly in the brain (Choate et
al., 2003; Xu et al., 2000). WNK1 has been shown to be co-localized with Lingo-1 in cortical cultured
neurons (Zhang et al., 2009) in addition to being shown as a direct binding partner to Lingo-1 through
co-immunoprecipitation experiments with both brain tissue and cell lysates (Zhang et al., 2009).
Considering that little is known about the regulation and function of WNK1 in the central nervous
system, there are an abundance of genetic studies regarding WNK1 gene (located on chromosome
12p13.3) mutations. Interestingly, the disruption of the WNK1 gene in mice leads to death of the
embryo at day 13 (Zambrowicz et al., 2003), suggesting an essential role of WNK1 in embryonic and
neural development, which is a critical period implicated in a number of neurological and
neuropsychiatric disorders. Furthermore, large intronic deletions in the WNK1 gene, leading to an
increase in WNK1 mRNA, have been linked to an inheritable hypertension syndrome (Wilson et al.,
2003), in addition to genetic variations located in the regulatory 5’ region of the WNK1 gene also
being associated with hypertension (Han et al., 2011). WNK1 gene expression has also been
consistently reported to be upregulated in the prefrontal cortex of schizophrenia sufferers in genome
wide association studies (Maycox et al., 2009; Mistry et al., 2012), suggesting a role in this disorder
as well.
The suppression of WNK1 expression by RNA interference has been shown to promote neurite
extension and eliminate the inhibitory response to Nogo in cortical cultured neurons. In addition, the
overexpression of WNK1 (123-510) reduces Nogo-induced inhibition of neurite extension rather than
strengthening it, and inhibits the activation of RhoA (Zhang et al., 2009). The over expression of
WNK1 (123-510) was also found to significantly reduce the interaction between endogenous WNK1
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and Lingo-1, suggesting that this serine threonine kinase may serve as a binding platform for Lingo-1,
however the kinase activity may not be necessary for Lingo-1 signaling (Zhang et al., 2009).
3.3. Myt1 and Myt1l
Myelin Transcription Factor 1 (Myt1) and its homologue Myelin Transcription Factor 1-like (Myt1l)
are postmitotic neuronal specific zinc finger proteins expressed in the developing brain (Armstrong et
al., 1995; Bellefroid et al., 1996). They are coded for by two independent genes Myt1 and Myt1l
respectively on human chromosomes 20q13.33 and 2p25.3. Myt1 expression appears to be present in
both neural and glial lineages, however in the adult brain, Myt1 is not expressed on neurons
(Armstrong et al., 1997). In contrast, Myt1l does not appear to be found in either the glial lineage, nor
on glial cells in the adult brain, however its transcripts are most abundantly expressed in the prenatal
brain during the development of neurons and in differentiating neurons suggesting that it plays an
important role in neuronal differentiation (Kim et al., 1997).
Myt1l has been reported to directly interact with the intracellular domain of Lingo-1, suggesting that
Lingo-1 may regulate Myt1l transcription factor activity by affecting its subcellular localization
(Llorens et al., 2008). It is thought that this may occur in two different ways: firstly Lingo-1 may
interact with Myt1l to regulate its transcription factor activity by retaining it in the cytoplasm; or
secondly, Lingo-1 may transduce intracellular signals by docking additional Myt1l cofactors or
modifying enzymes (Llorens et al., 2008). Myt1 and Myt1l display a high degree of identity, and
therefore are highly likely to share the same binding sites, considering the ability of the Myt1l protein
to bind the oligonucleotide sequence containing the proteolipid protein site that was originally
intended to clone Myt1. It has therefore been suggested that Lingo-1 may interact with Myt1 in
oligodendrocytes the way that Lingo-1 interacts with Myt1l in neurons. Since it is known that Lingo-1
expression in oligodendrocytes and neurons is necessary for preventing myelination, it seems
reasonable to hypothesize that these effects are mediated by an interaction between Lingo-1 and Myt1
and Lingo-1 and Myt1l in oligodendrocytes and neurons respectively (Llorens et al., 2008). Lingo-1
and Myt1 gene expression have been found to be increased when adult nerve cells were exposed to
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traumatic injuries and in demyelinated lesions in rodent and human central nervous system injuries
respectively (Mi et al., 2004; Vana et al., 2007).
3.4. EGFR/PI3-K/Akt Pathway
The Epidermal Growth Factor Receptor (EGFR), also known as ErbB-1, triggers the activation of the
Phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway leading to DNA synthesis and cell
proliferation including neuronal survival and growth (Brunet et al., 2001; Inoue et al., 2007; Oda et
al., 2005). The binding of myelin inhibitors to NgR, has been shown to trigger phosphorylation of
EGFR in a Ca2+ dependent manner (Koprivica et al., 2005), however EGFR activation by its own
ligand, Epidermal Growth Factor (EGF), is not sufficient to inhibit axonal-outgrowth (Koprivica et
al., 2005), thus it is reasonable to speculate that receptor transactivation of EGFR by the NgR
complex may activate a different set of signaling cascades (Schwab et al., 2006). More recently
studies have shown that some LRR Ig-containing proteins are able to influence growth factors by
modulating pathways related to EGFR signaling (Goldoni et al., 2007; Gur et al., 2004), indicating
that it may in fact be due to Lingo-1 signaling that NgR is able to affect EGFR. Lingo-1 has since
been shown to directly bind to EGFR using the EGFR-like tyrosine phosphorylation site in its
cytoplasmic domain to negatively regulate the EGFR/Akt signaling pathway, which has been notably
implicated in the pathophysiology of schizophrenia (Huang and Chen, 2009; Inoue et al., 2007; Koros
and Dorner-Ciossek, 2007). Through immunoprecipitation, cell culture and brain tissue experiments,
endogenous Lingo-1 was found to reduce EGFR levels mediated by a direct physical interaction
(Inoue et al., 2007).
However the complete mechanisms underlying the inhibition of EGFR expression and function by
Lingo-1 remain unclear. It has been suggested that this inhibition may be caused by Lingo-1
accelerating the internalization and degradation of EGFR and so reducing the availability of EGFR on
the neuronal membrane. Another potential mechanism suggests that Lingo-1 can directly inhibit the
phosphorylation of EGFR and thus decrease PI3-K/Akt signaling pathway activity, resulting in
decreased neuronal survival and growth (Inoue et al., 2007). The potential role of Lingo-1 as an

13

inhibitor of neuronal survival through the Akt signaling pathway enhances the hypothesis of a role of
Lingo-1 signaling in the pathogenesis of a number of neuropsychiatric disorders. Considering the role
of Lingo-1 in directly negatively regulating the EGFR/PI3-K/Akt signaling pathway, Lingo-1 has
been investigated in relation to dopamine neuron survival, growth and function (Inoue et al., 2007). It
was found that all of these factors were improved with Lingo-1 antagonism, and that inhibiting Lingo1 also increased EGFR and phospho-Akt levels in the absence of myelin inhibitors and promoted
retinal cell survival (Fu et al., 2008; Inoue et al., 2007).
Interestingly, downstream Lingo-1 signaling partners WNK1 and Myt1 have also been shown to be
implicated in EGFR/PI3-K/Akt signaling. WNK1 has been identified as a substrate for Akt signaling,
and the phosphorylation of WNK1 is inhibited by PI3-K inhibitors, thus suggesting that WNK1 is
phosphorylated via the PI3-K/Akt signaling pathway (Jiang et al., 2005). Furthermore, Myt1 was
reported to be inhibited and significantly downregulated by Akt phosphorylation (Okumura et al.,
2002).
Since Lingo-1 signaling plays a pivotal role in repressing neurite outgrowth, oligodendrocyte
differentiation and myelination and keeping in mind its expression at an early stage of development,
the implication of Lingo-1 and its signaling pathways in a wide variety of neurological pathologies
seems apparent.
4. Role of Lingo-1 in Neurological Pathologies
A wide range of central nervous system diseases including spinal cord injury, traumatic brain injury,
multiple sclerosis, Parkinson’s disease and essential tremor, as well as Alzheimer’s disease, epilepsy
and glaucoma; are neurodegenerative disorders resulting in neuronal death, axon degeneration, gliosis
and demyelination. Lingo-1 and its signaling partners have been shown to be implicated in all of these
disorders, due to their role in the inhibition of axonal outgrowth, neuronal death, oligodendrocyte
differentiation and myelination (see Figure 1 and Supplementary Materials). Furthermore, a number
of preclinical studies have shown that various methods of antagonizing Lingo-1 result in neuronal and
oligodendroglial survival, axonal growth and remyelination.
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4.1. Spinal Cord Injury, Traumatic Brain Injury and Multiple Sclerosis
The vast majority of studies on Lingo-1 in neuropathological states are performed in relation to
multiple sclerosis and traumatic injury to the central nervous system due to the inhibitory role of
Lingo-1 in neurite outgrowth, oligodendrocyte differentiation and myelination, hindering the
regeneration of the injured nervous system, whether from endogenous or exogenous processes.
Spinal cord injury results in damage to the axonal tracts that are responsible for controlling motor and
sensory function (Ji et al., 2006). Lingo-1 has been shown to be detected in the axonal tracts of
adolescent rat spinal cords following injury (Mi et al., 2004). Further to this, a five-fold increase in
Lingo-1 mRNA levels was detected at 14 days post injury (Mi et al., 2004). Lingo-1-Fc, a soluble
form of Lingo-1, has also been shown to antagonize Lingo-1 signaling pathways by inhibiting the
binding of Lingo-1 to NgR, resulting in vast improvements in the functional recovery of rats
following lateral hemisection of the spinal cord. Additionally these rats displayed elevated levels of
axonal sprouting and increased oligodendrocyte and neural survival due to Lingo-1-Fc blocking RhoA
activation (Ji et al., 2006). Lingo-1-Fc treatment was also found to enhance plasticity in the injured
spinal cord through the promotion of sprouting of collateral neurons; however whether Lingo-1-Fc is
able to promote cortical plasticity remains to be determined (Ji et al., 2006). These data demonstrate a
functional role of Lingo-1 in vivo and suggest that Lingo-1 may be a viable target for the treatment of
spinal cord injury.
Traumatic brain injury characteristically involves the necrotic and apoptotic death of cells in the brain
in vulnerable areas such as the cerebral cortex and hippocampus (Conti et al., 1998; Raghupathi,
2004; Royo et al., 2003), two areas known to highly express Lingo-1 in both the adult stage of life and
throughout development (Carim-Todd et al., 2003; Mi et al., 2004). RhoA signaling is largely
responsible for the neuronal response to neuronal inhibitory proteins and the regeneration (or lack
thereof) of damaged axons (Dubreuil et al., 2006). Significant RhoA upregulation (Brabeck et al.,
2004) and activation has been reported in both the cortex and hippocampus following traumatic brain
injury (Dubreuil et al., 2006). The activation of Rho GTPases occurs during synaptic remodeling,
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neuronal activity and synaptic plasticity in the central nervous system (Luo, 2002; O’Kane et al.,
2004, 2003). Since it is widely established that Lingo-1 mediates axonal outgrowth, oligodendrocyte
differentiation and axon myelination largely due to its interaction with, and activation of RhoA, it has
been hypothesized that Lingo-1 plays a significant inhibitory role in this debilitating neurological
disorder. In support of this, the NgR inhibitor MAG has been shown to consistently improve a number
of behavioural outcomes in rats using an experimental traumatic brain injury paradigm (Thompson et
al., 2006). Furthermore, Lingo-1 antagonism using Lingo-1-Fc, has been shown to inhibit RhoA
activation both in vitro in cultured cerebellar granule neurons (Mi et al., 2004), and in vivo in models
of spinal cord injury (Ji et al., 2006). Since Lingo-1-Fc is able to block the interactions between
Lingo-1 and NgR, it seems reasonable that blockade of RhoA activation occurred at the level of
Lingo-1/NgR/p75 or TROY complex.
In addition to its role as part of the NgR trimolecular receptor complex in neuronal processes, Lingo-1
has also been shown to be expressed on oligodendrocytes where it able to negatively modulate
oligodendrocyte differentiation and axon myelination (Mi et al., 2005). Lingo-1-Fc was found to have
a neuroprotective effect on the survival of both neurons and oligodendrocytes after spinal cord injury
in rats (Ji et al., 2006). Furthermore antagonizing endogenous Lingo-1 either by Lingo-1 RNA
interference, dominant-negative Lingo-1, an anti-Lingo-1 antibody, or soluble Lingo-1; resulted in
more highly differentiated and mature oligodendrocytes (with more branching and increases in the
lengths of processes), in addition to the formation of abundant myelin sheaths (Mi et al., 2005). As a
result of these experiments, Lingo-1 antagonists were examined as a potential candidate in the
treatment for multiple sclerosis. Although the underlying molecular mechanisms constituting the
presentation of multiple sclerosis remain unknown, the degree of inflammatory demyelination in this
debilitating disorder correlates significantly with the extent of axonal damage that begins in the early
stages of multiple sclerosis (Lassmann, 2003).
Lingo-1 protein expression has been shown to be decreased in both the prefrontal cortex and
cerebellar cortex of multiple sclerosis brains, while expression of its co-receptor TROY was found to
be significantly increased in the same brain regions compared to samples from subjects without
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multiple sclerosis (Satoh et al., 2007). However due to the very limited sample size used in this study,
the results have to be considered with caution. In contrast to this result, the immunoreactivity of both
Lingo-1 and TROY were found to be enhanced in subpopulations of astrocytes and
macrophages/microglia from the prefrontal and parietal cerebral cortex in multiple sclerosis brains
(Satoh et al., 2007). Additionally, levels of NgR are up-regulated in reactive astrocytes and
macrophages/microglia in chronic active demyelinating lesions of multiple sclerosis (Satoh et al.,
2005), suggesting the implication of the Lingo-1/NgR/TROY signaling complex in the glial-neuronal
and glial-glial interactions underlying multiple sclerosis. Considering these significant interactions,
Garcia-Martin et. al. (García-Martín et al., 2013) set out to investigate two Lingo-1 variants
(rs9652490 and rs11856808), previously associated with other neurological pathologies including
essential tremor (Stefansson et al., 2009; Vilariño-Güell et al., 2010a) and Parkinson’s disease
(Vilariño-Güell et al., 2010a, 2010b). Despite no significant associations being found between these
genetic variants and multiple sclerosis in a Caucasian Spanish population (García-Martín et al., 2013),
evidence continues to stack up further implicating Lingo-1 in the pathogenesis of multiple sclerosis.
This is further illustrated by animal studies. Myelination of central nervous system axons in Lingo-1
knockout mice was found to present earlier in life compared to their wild-type littermates (Mi et al.,
2007). In addition these mice have a greater resistance to the development of MOG-induced
experimental autoimmune encephalomyelitis (EAE) (Mi et al., 2007), a model commonly used to
model human demyelinating diseases including multiple sclerosis. Furthermore, treatment with
Lingo-1 antagonizing antibodies and by RNA interference, leads to functional recovery and increases
the axonal integrity of mice with (EAE) (Mi et al., 2007; Wang et al., 2014). Lingo-1 antagonism has
been shown to induce both oligodendrocyte differentiation and remyelination using three different
demyelination animal models; the EAE model, and pharmacological toxin-induced models of
demyelination: lysophosphatidylcholine-(LPC) and cuprizone (Mi et al., 2009).
The promising results of antagonizing Lingo-1 to treat demyelination has led to the development of
BIIB033 (also known as Li81); the first fully human, IgG1 monoclonal Lingo-1 antibody to enter
clinical development (Mi et al., 2013). BIIB033 has been specially engineered to have reduced Fc
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gamma and complement effector functions compared with wild type IgG, and binds human Lingo-1
with high affinity and specificity (Mi et al., 2013). Stage I clinical trials have demonstrated that
BIIB033 is safe for use in humans, both in healthy controls, and multiple sclerosis patients, and has
been found to be well tolerated, up to 100 mg/kg, and is able to cross the blood brain barrier resulting
in cerebral spinal fluid levels of greater than 90% effective concentration when given at intravenous
doses of greater than 10 mg/kg (Tran et al., 2012, 2014). Further to this, structural studies examining
how BIIB033 binds to Lingo-1 have shown that its binding to the convex surface of the leucine-rich
repeat domain of Lingo-1 within repeats 4-8, blocks the Lingo-1-Lingo-1 contact points and prevents
oligomerization of the protein (Pepinsky et al., 2014). This indicates that BIIB033 interferes with the
ability of Lingo-1 to form homotetramers, with the rearrangement of the quaternary structure of
Lingo-1 providing a model for how the antibody inhibits Lingo-1 function in oligodendrocytes
(Pepinsky et al., 2014). Phase II clinical trials for BIIB033 are currently underway, and will provide
vital information on the impact of targeting Lingo-1 as a treatment for multiple sclerosis (Brugarolas
and Popko, 2014).
4.2. Parkinson’s Disease and Essential Tremor
Parkinson’s disease and essential tremor are age-related movement disorders which have a prevalence
of approximately 1-2% and 3-6% of individuals over the age of 65 respectively (de Rijk et al., 2000;
Louis et al., 2009). While the clinical presentation of Parkinson’s disease and essential tremor do
overlap, essential tremor patients typically present with tremor on action, or postural tremor, whereas
Parkinson’s symptoms are typically more severe in that they present as tremor at rest, usually
asymmetrical, in addition to experiencing bradykinseia, rigidity and postural instability (Fekete and
Jankovic, 2011; Shahed and Jankovic, 2007).
Lingo-1 was first implicated in Parkinson’s disease, when it was discovered that levels of Lingo-1 are
upregulated in the substantia nigra of post mortem Parkinson’s disease brains compared to matched
controls and in neurotoxic animal models of Parkinson’s disease (Inoue et al., 2007). Lingo-1
antagonism by a variety of pharmacological and genetic mechanisms produces neuroprotective effects
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on dopaminergic neurons in the midbrain (Inoue et al., 2007). Dopamine neuron survival and a
significant reduction in behavioural abnormalities were observed in Lingo-1 knockout mice compared
to wild-types (Inoue et al., 2007). Similar effects were also observed in wild-type mice in vivo, and in
vitro in cultured dopaminergic neurons treated with Lingo-1 antagonists (Inoue et al., 2007). The
treatment of dopaminergic neurons with a dominant-negative form of Lingo-1, an anti-Lingo-1
antibody, and Lingo-1-Fc resulted in a significant improvement in neuronal survival during a
mitochondrial toxicity paradigm used to model Parkinson’s disease in vitro (Inoue et al., 2007).
Interestingly, the neuroprotection observed in in vivo and in vitro studies, was accompanied by an
activation of the EGFR/PI3-K/Akt signaling pathway which is also implicated in the pathology of
Parkinson’s disease (Brunet et al., 2001; Farkas and Krieglstein, 2002; Iwakura et al., 2005; Onyango
et al., 2005; Timmons et al., 2009). As mentioned above in section 3.4, Lingo-1 is able to directly
bind to EGFR (Inoue et al., 2007), therefore the pharmacological inhibition of Lingo-1 by the Lingo-1
antagonists, suppresses its binding to EGFR resulting in activation of the EGFR/PI3-K/Akt signaling
in the in vitro and in vivo models of Parkinson’s disease (Inoue et al., 2007).
Expression of Lingo-1 protein has been found to be significantly increased in the cerebellum
(particularly at the basket cell pinceau along the purkinje cell axon initial segment), but not in the
occipital cortex of essential tremor patients (Kuo et al., 2013). The highly enriched pinceau processes
labeled with Lingo-1 were not only more commonly observed in the cerebellum of essential tremor
patients compared to controls, but were also significantly more elongated in the cerebellum of
essential tremor patients compared to those seen in both cerebellar degenerative disorder patients and
controls (Kuo et al., 2013). This suggests that Lingo-1 pinceau are a common feature of both essential
tremor and cerebellar degenerative disorder, however the longer pinceau processes are specific to the
essential tremor pathology, providing a novel pathological link between Lingo-1 and essential tremor.
While environmental factors are proposed to play a role in the onset of both Parkinson’s disease and
essential tremor, a number of genetic factors have been recognized to contribute to both disorders
(Deng et al., 2007; Spanaki and Plaitakis, 2009). There is an abundance of genetic evidence
implicating Lingo-1 with both Parkinson’s disease and essential tremor (Vilariño-Güell et al., 2010a,
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2010b), with an equal number of studies claiming no implication of Lingo-1 genetic variations with
these disorders (Białecka et al., 2010; Wu et al., 2011). As a result, in 2012 meta-analyses were
conducted on the results of genetic studies for both Parkinson’s disease and essential tremor and it
was confirmed that the Lingo-1 single nucleotide polymorphisms (SNPs) rs9652490 and rs11856808
of which both had been claimed to be both associated and not associated with essential tremor, were
in fact associated with the disorder (Jiménez-Jiménez et al., 2012). In the case of Parkinson’s disease
the rs9652490 SNP was found not to have an association with Parkinson’s disease following the metaanalysis (Wu et al., 2012).
4.3. Alzheimer’s Disease
Alzheimer’s disease is the most prevalent cause of dementia in humans and is typically characterized
by the early loss of neocortical synapses, the formation of neurofibrillary tangles and the
accumulation of neuritic plaques within the hippocampus and temporal cortical regions of the brain
(Khachaturian, 1985). One of the most hypothesized causes of the memory decline in the aging brain
is the failure of synaptic plasticity with age (Foster, 1999). Lingo-1/NgR/p75 or TROY signaling was
examined in the hippocampus and cerebral cortex from rats in an aging brain study (Trifunovski et al.,
2006). While there were no significant alterations observed in the mRNA expression of any of the
receptor components or in the expression of the ligands OMgp or MAG; Nogo mRNA was found to be
significantly reduced in hippocampal subregions, specifically the CA1, CA3, CA4 and dentate gyrus,
with age. Additionally, a downregulation of NgR mRNA expression was supposedly caused by
activity induced alterations in brain activity, which is required to induce plastic changes within the
brain (Josephson et al., 2003). In addition, a simultaneous increase in both NgR and its ligand Nogo
were hypothesized to be required to induce a locked conformational state in hippocampal and cortical
microcircuitry in order to maintain the plastic changes (Josephson et al., 2003). Thus the decrease in
Nogo mRNA expression in the hippocampus of aged animals may be related to the age-dependent
decline of brain plasticity.
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In contrast to these animal studies, Zhu et. al. have reported the expression of NgR to be increased in
the hippocampus of Alzheimer’s disease patients (Zhu et al., 2007). While there was not an overall
significant difference in the number of immunopositive NgR neurons in Alzheimer’s disease
compared to control patients, there was a significant increase in the ratio observed between NgR
immunopositive neurons to the total number of neurons within the hippocampus of Alzheimer’s
patients compared to that of the control group. Additionally, NgR was found to be co-localized with
the hyperphosphorylated tau protein, which is largely responsible for the formation of neurofibrillary
tangles, in hippocampal cells of Alzheimer’s disease patients compared to controls.
The hypothesis of dysfunctional Lingo-1 signaling in Alzheimer’s disease is also supported by a
report of enriched Lingo-1 expression within the limbic system (Carim-Todd et al., 2003), a region
largely affected in Alzheimer’s disease (Thiebaut de Schotten et al., 2014). In addition, NgR was
found to be involved in the formation and deposition of amyloid-β peptide (Park et al., 2006), the
main component in plaque formations (Hu et al., 2002). Due to is role in neuronal apoptosis and cell
death, and more recent implication in the formation of neurofibrillary tangles, p75 also has a proposed
role in the pathogenesis of Alzheimer’s disease (Hu et al., 2002). Similarly, Lingo-1 has been shown
to directly bind to amyloid precursor protein, the precursor for amyloid-β peptide, and to modulate its
processing by increasing the production of amyloid-β peptide from amyloid precursor protein when it
is overexpressed (Bai et al., 2008); however this was not found to be modulated by the leucine-rich
repeats of Lingo-1 (Stein and Walmsley, 2012). Additionally, Lingo-1 is able to regulate amyloid
precursor protein proteolysis by interacting with amyloid precursor protein in the endosome/lysosome
pathway where Lingo-1 can control and regulate the amount of amyloid precursor protein available
for processing (de Laat, 2012). All of the above evidence supports the hypotheses that Lingo1/NgR/p75 signaling is implicated in the pathophysiology of Alzheimer’s disease.
Furthermore, pharmacological blockade of EGFR antagonizes the formation of amyloid-β oligomers
induced by EGFR activation, and improves memory impairment in animal models of Alzheimer’s
disease, suggesting that EGFR would be an ideal target for Alzheimer’s disease therapy (Wang et al.,
2012). Since Lingo-1 can directly activate EGFR and due to its role in neuronal survival, we can
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hypothesis that Lingo-1 may also be involved in the pathophysiology of Alzheimer’s disease through
its interaction with EGF and EGFR.
4.4. Tuberous Sclerosis, Focal Cortical Dysplasia and Temporal Lobe Epilepsy
Tuberous sclerosis, focal cortical dysplasia and temporal lobe epilepsy are all very different types of
neurological disorders; however they all have a common symptom: seizures. The expression of
components of the Nogo-A signaling system have been investigated in samples taken from pediatric
patients with tuberous sclerosis and focal cortical dysplasia type IIb, who were undergoing surgical
procedures for the treatment of epilepsy. Both of these disorders are characterized by malformations
of the cortex during development and as mentioned above, are both frequently associated with
seizures (Yu et al., 2012). Both protein and mRNA levels for Nogo-A, NgR, Lingo-1, TROY and
RhoA but not p75 were found to be upregulated in the cortex of patients from both tuberous sclerosis
and cortical dysplasia compared to controls. Interestingly Nogo-A, NgR, Lingo-1 and TROY were all
highly expressed in misshapen cells including dysmorphic neurons, balloon cells and giant cells (Yu
et al., 2012). Lingo-1 and TROY were also identified in reactive astrocytes of the patient samples
compared to controls. Together this research suggests that Nogo-A along with its signaling complex
Lingo-1/NgR/TROY, but not Lingo-1/NgR/p75 may contribute to the development and/or progression
of seizure activity in malformations of cortical development.
In addition the Lingo-1/NgR/TROY signaling complex was found to be altered in an animal model of
temporal lobe epilepsy; the BALB/cByJ-Kv1.1mceph/mceph (also known as mceph/mceph) mouse
(Lavebratt et al., 2006). Temporal lobe epilepsy is the most common type of adult focal epilepsy that
presents with progressive complex partial seizures with pathological brain overgrowth, or
megalencephaly. Temporal lobe epilepsy principally affects the hippocampus and ventral cortex.
Megalencephaly is a developmental disorder affecting around 2% of children worldwide and is
largely thought to be caused by genetic abnormalities in the PI3-K/Akt signaling pathway which is
known to be activated by Lingo-1 signaling. NgR mRNA expression was found to be significantly
increased in the dentate gyrus in mceph/mceph mice compared to wild-types, with no other brain
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regions displaying significant genotypic alterations in NgR expression. The NgR expression was
however specifically restricted to neurons and predominantly observed in regions associated with high
plasticity such as the cortex and hippocampus, both of which were also significantly enlarged in
mceph/mceph mice compared to wild-types (Lavebratt et al., 2006). Additionally, Lingo-1 showed
expression patterns throughout the brain similar to that of NgR, however a significant increase in
Lingo-1 was observed in the CA3 region of the hippocampus, in addition to in the dentate gyrus
ventral cortex and amygdala in the mceph/mceph mice compared to wild-types (Lavebratt et al.,
2006). The third member of the tripartite receptor complex TROY was the only component in the
complex to be significantly downregulated in the brains of mceph/mceph mice; with the most
prominent decrease being evident in the cortex and dentate gyrus, with slightly smaller reductions
being evident in the CA1 region of the hippocampus and ventral cortex. Again these were all brain
regions that were significantly enlarged in mceph/mceph mice compared to wild-types. Importantly,
all of the dysregulations in the expression of NgR, Lingo-1 and TROY mRNA in the mceph/mceph
mice were normalized when the mice were treated with carbamazepine, a commonly used
anticonvulsant drug used for the treatment of epilepsy, with Lingo-1 dropping to levels even below
that of wild-type mice following treatment (Lavebratt et al., 2006). Additionally, the cortical
overgrowth in brain regions that were enlarged due to the genetic abnormality in the mceph/mceph
mice was prevented by the treatment with carbamazepine. Furthermore, an alteration of the
EGF/mTOR (mammalian target of rapamycin) signaling pathway has also been reported in the
pathophysiology of epilepsy (Cho, 2011). Due to the direct inhibitory effects of the EGF/EGFR
signaling pathways, the implication of Lingo-1 through the EGF-mTOR pathway also seems
appropriate in the context of epilepsy.
Altogether, these results suggest that the Lingo-1/NgR/TROY and EGF/EGFR signaling pathways are
involved in temporal lobe epilepsy, and that treatment with carbamazepine may be an effective
treatment not only for seizures, but also for megalencephaly.
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4.5. Glaucoma
Since the optic nerve is still considered to be a part of the central nervous system, the role of Lingo-1
in optic nerve disorders has been investigated. Glaucoma is a neurodegenerative disease characterized
by abnormally high intraocular pressure and is the leading cause of blindness due to retinal ganglion
cell death. Both Lingo-1 and NgR were found to be significantly upregulated in retinal ganglion cells
following the use of an ocular hypertension paradigm in rats (Fu et al., 2011, 2008). Antagonizing the
function of Lingo-1, either using Lingo-1-Fc or an anti-Lingo-1 antibody, or antagonizing NgR using
soluble NgR (sNgR-Fc) has been shown to not only reduce the number of retinal ganglion cells that
were lost after ocular hypertension, but also promote the survival of retinal ganglion cells following
optic nerve transection (Fu et al., 2011, 2008). Lingo-1-Fc treatment was also shown to block RhoA
signaling and promote Akt activation (Fu et al., 2008), thus the mechanism underlying Lingo-1
antagonist induced neuroprotection is evidently mediated through the RhoA and PI3-K/Akt signaling
pathways. Conversely, another two studies have shown that Lingo-1 may exert its neuroprotective
effects on retinal ganglion cells following ocular hypertension by its interaction with BDNF/TrkB
(tropomyosin receptor kinase B). Lingo-1 and BDNF were found to be co-expressed in retinal
ganglion cells (Fu et al., 2009). Additionally Lingo-1 is able to form a complex with TrkB following
ocular hypertension injury (Fu et al., 2010). Furthermore it was demonstrated that Lingo-1 antagonists
(Lingo-1-Fc and an anti-Lingo-1 antibody) caused an upregulation of phospho-TrkB phosphorylation,
leading to the survival of retinal ganglion cells (Fu et al., 2010). However a combined treatment of
BDNF and Lingo-1-Fc resulted in activation of more TrkB than a treatment of BDNF alone (Fu et al.,
2009). Since the neuroprotective effects could be inhibited by an anti-BDNF antibody, this indicates
that the regulation of the BDNF/TrkB signaling pathway by Lingo-1 is responsible for mediating the
survival of the retinal ganglion cells.
Most recently, myocilin has been identified as being involved in the Lingo-1/NgR mediated
oligodendrocyte differentiation and myelination of the optic nerve (Kwon et al., 2014). Myocilin is a
glycoprotein secreted by optic nerve astrocytes, and mutations in its gene MYOC, were the first
genetic implications known to cause glaucoma, more specifically open-angle glaucoma (Stone et al.,
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1997). In both in vivo and in vitro studies, myocilin was found to mediate oligodendrocyte
differentiation through direct interaction with both Lingo-1 and NgR (Kwon et al., 2014).
Furthermore myocilin is involved in the myelination of the optic nerve in mice, and the differentiation
of optic nerve oligodendrocytes is significantly delayed in Myocilin knockout mice, leading to
decreased thickness of the myelin sheaths on the optic nerves of these mice compared to wild types.
Overall these novel results have shown that myocilin plays a role in oligodendrocyte differentiation
and myelination through its interactions with the Lingo-1/NgR complex.
5. Lingo-1 Signaling: A New Role in Psychiatric Disorders
Dysfunction of axonal growth and myelination has been prominently implicated by gene expression,
histopathology and imaging studies, in a wide range of neuropsychiatric disorders including
depression (Alexopoulos et al., 2002; Aston et al., 2005; Bae et al., 2006; Hannestad et al., 2006),
obsessive compulsive disorder (Cannistraro et al., 2007; Jayarajan et al., 2012; Szeszko et al., 2005),
post-traumatic stress disorder (Abe et al., 2006; Kim et al., 2005, 2006), bipolar disorder (Adler et al.,
2006, 2004), autism (Keller et al., 2007; Lange et al., 2010; J. E. Lee et al., 2007), and attention
deficit hyperactivity disorder (Castellanos et al., 2003; Filipek et al., 1997; Rüsch et al., 2007;
Semrud-Clikeman et al., 2000). However the vast majority of studies have shown an implication of
axonal growth and myelination dysfunction in schizophrenia (Barley et al., 2009; Bartzokis et al.,
2003; Hakak et al., 2001; Schmitt et al., 2004; Shenton et al., 2001; Tkachev et al., 2003; Uranova et
al., 2001; Walterfang et al., 2011, 2006).
Until recently, no studies had ever specifically investigated a link between Lingo-1 in schizophrenia.
We have provided the first evidence of an implication of Lingo-1 in schizophrenia, by observing
alterations in the expression profiles of Lingo-1 and its signaling partner proteins in the dorsolateral
prefrontal cortex (DLPFC) and hippocampus (CA1 and CA3) from post-mortem schizophrenia brains
(Fernandez-Enright et al., 2014); regions highly relevant to the schizophrenia pathophysiology
providing highly sought after, novel directions for therapeutic strategies.
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Although Lingo-1 itself had never been implicated in schizophrenia, a number of nicotinic receptor
genes and the myelination gene Lipidosin, located within the vicinity of the Lingo-1 locus at
chromosomic region 15q24, had previously been shown to be associated with schizophrenia, along
with several other myelination genes which were also reported to be downregulated in the prefrontal
cortex in this disorder (Hakak et al., 2001; Tiwari et al., 2005; Tkachev et al., 2003; Weidenhofer et
al., 2006). With Lingo-1 being a known myelination inhibitor and a negative modulator of
oligodendrocyte differentiation when overexpressed (Mi et al., 2005), the investigation of the role of
Lingo-1 in schizophrenia seemed timely and topical.
Previous studies have described significant reductions in prefrontal lobe white matter volume in
patients with schizophrenia (Breier et al., 1992; Buchanan et al., 1998). However, a decrease in white
matter anisotropy was consistently reported in schizophrenia patients, irrespective of their white
matter volume (Buchsbaum et al., 1998; Lim et al., 1999; Tang et al., 2007). Thus, schizophrenia
patients could present with compromised neuronal connectivity and/or directional coherence of white
matter fibers (Lim et al., 1999), possibly due to the reported upregulation of Lingo-1 in schizophrenia
(Fernandez-Enright et al., 2014).
In support of the possible role of Lingo-1 in myelin dysfunction in schizophrenia, Lingo-1 knockout
mice have been shown to have a higher and more differentiated percentage of mature
oligodendrocytes than wild types (Mi et al., 2007, 2005). The typical onset of myelination in wild
type mice occurs at PN5, however Lingo-1 knockout mice had already developed myelinated fibers at
PN1. Additionally, no obvious changes were observed in the peripheral nervous system sciatic nerve,
suggesting that myelination effects were limited to the central nervous system (Mi et al., 2005).
As described above in section 4, Lingo-1 has been repeatedly implicated in a wide variety of central
nervous system disorders resulting in emotional and mental disturbances, loss of motor skills and
cognitive deficits; however in addition to its novel implication in schizophrenia (Fernandez-Enright et
al., 2014), there is also evidence implicating the Lingo-1 chromosomic region 15q24 in a range of
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neuropsychiatric disorders including autism spectrum disorder, and anxiety disorders such as panic
and phobic disorders.
To date, 15q24 deletion syndrome has been examined in a number of autism spectrum disorder
cohorts, and from these studies, 15q24 deletion syndrome has been identified in approximately 0.10.2% of individuals with autism spectrum disorders (Marshall et al., 2008; McInnes et al., 2010).
However to our knowledge, of the individuals identified as having 15q24 deletion syndrome to date,
21% of subjects present with autism spectrum disorder (Marshall et al., 2008; McInnes et al., 2010),
and another 7% present with autistic features (McInnes et al., 2010; Sharp et al., 2007). Despite these
implications, the true frequency of autism spectrum disorders in patients with 15q24 deletion
syndrome is currently not known, as not all 15q24 deletion syndrome patients have been assessed for
autism.
Further to this, mild mental retardation and/or developmental delay is present in all patients identified
as having microduplications in the 15q24 chromosomic region (El-Hattab et al., 2010, 2009; Kiholm
Lund et al., 2008), in addition to one patient also testing positive for both Asperger’s syndrome, and
attention deficit hyperactivity disorder (El-Hattab et al., 2009). Moreover interstitial duplications in
15q24-26, engulfing Lingo-1 in its entirety, have been significantly associated with panic,
agoraphobia and social phobia in families, and with panic disorder in non-familial cases, with 90% of
patients fitting the diagnosis of one or more of the anxiety disorders having the chromosomic
duplication (Gratacòs et al., 2001). Despite a number of groups trying to reproduce this finding, none
have successfully done so (Henrichsen et al., 2004; Tabiner et al., 2003; Weiland et al., 2003; Zhu et
al., 2004), therefore the finding by Gratacòs et. al. must be considered with caution.
While Lingo-1 and its co-receptor NgR are highly involved in neurodevelopmental processes such as
axonal outgrowth, they also play important roles in the mature brain. Both of these proteins have been
previously reported to regulate experience-dependent synaptic plasticity (Josephson et al., 2003;
McGee et al., 2005; Trifunovski et al., 2004), one of the important foundations in the development of
learning and memory which has been shown to be dysfunctional in schizophrenia.
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The results of our novel study, in concert with the current literature, suggest that downregulation of
NgR and concurrent upregulation of Lingo-1 may be activity dependent characteristics of synaptic
plasticity in schizophrenia. There is an abundance of evidence now supporting the concept that
alterations in activity dependent plasticity (Shatz, 2009; Stephan et al., 2006), and changes in the
restriction of myelin based plasticity genes in the postnatal brain, may be the underlying factor for the
many cognitive and behavioural deficits reported in schizophrenia (C. J. Carter, 2006; C. S. Carter,
2006; Davis et al., 2003; Davis and Haroutunian, 2003; Hakak et al., 2001). It has previously been
considered that aberrant enhancement of neuronal plasticity during neural development in
schizophrenia may be caused by a reduction or complete loss of NgR function (Budel, 2007; Budel et
al., 2008); this is supported by our study demonstrating a downregulation of NgR in schizophrenia
subjects (Fernandez-Enright et al., 2014). Furthermore, this is also supported by the presence of
genetic variations in the NgR gene in 1-2% of the schizophrenia population (Budel, 2007; Budel et al.,
2008; Karayiorgou et al., 1995; Sinibaldi et al., 2004). Deletion of the chromosomic region 22q11, has
an association with a risk of schizophrenia 25 times greater than the general population, making the
22q11 deletion one of the strongest known genetic risk factors for schizophrenia (Bassett et al., 2003;
Bassett and Chow, 1999). Further to this, children and adolescents with the 22q11 deletion have been
found to have a high incidence of anxiety, depression, social withdrawal, attention deficit
hyperactivity disorder, bipolar disorder, obsessive-compulsive behaviors and occasionally autism
(Carlson et al., 1997; Kozma, 1998; Papolos et al., 1996; Woodin et al., 2001). Moreover, a
spontaneous 3 Mb deletion at 22q11 has been found in 5.3% of patients in the largest cohort of veryearly onset childhood onset schizophrenia subjects to date (Sporn et al., 2004). Additionally, SNPs
with functional roles and/or those resulting in a change in amino-acids (R377W, R227C, R399W,
rs74315508, rs74315509 and L18L) within the NgR gene have been previously identified in
schizophrenia subjects (Budel et al., 2008; Sinibaldi et al., 2004). Interestingly, two non-synonymous
changes (rs74315508 and rs74315509) were found in patients who displayed predominantly negative
symptoms which were strongly resistant to conventional and novel drug treatments (Sinibaldi et al.,
2004).
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It has been well documented that memory impairment exists in schizophrenia (Aleman et al., 1999;
Barch et al., 2001; Callicott et al., 2000; Weinberger et al., 1986). If impaired working memory is a
hallmark of schizophrenia, then a downregulation of NgR, and NgR gene mutations known to be
present in the schizophrenia population (Budel, 2007; Budel et al., 2008), could be considered
possible grounds for the development of this memory dysfunction taking into consideration the role of
NgR in regulating synaptic plasticity. In support of this hypothesis, NgR deficient mice have been
shown to exhibit impaired working memory, despite their spatial memory acquisition remaining intact
(Franowicz et al., 2002). NgR is the only established myelin associated inhibitor to display a memory
phenotype (Akbik et al., 2012); however since NgR knockout mice have also been shown to display
multiple schizophrenia related endophenotypes, a stronger link has been made between NgR
downregulation or loss, and schizophrenia (Budel, 2007). Additionally NgR knockout mice are now
considered to be an animal model for schizophrenia (Budel et al., 2008; Kim et al., 2004).
Either the p75 neurotrophin receptor or its functional homolog TROY make up the remainder of the
Lingo-1/NgR signaling complex, however despite the overwhelming evidence implicating NgR in
schizophrenia, only a few studies have reported levels of expression of p75 in the post-mortem
schizophrenia brain, where no change was reported in the hippocampus of schizophrenia subjects
compared to controls in the Stanley consortium brains, however a decrease in p75 binding was seen in
bipolar disorder subjects compared to controls in the same study (Dunham et al., 2009). Meanwhile,
alterations in p75 signaling proteins have been found in the post-mortem fusiform gyrus from autism
patients compared to controls; PI3-K and Akt were found to be significantly downregulated, and a
trend towards an upregulation of the p75 neurotrophin receptor was also found (Fahnestock and
Nicolini, 2014). Similar alterations were observed in the lateral temporal neocortex of rats using the
valproic-acid induced rat model of autism (Fahnestock and Nicolini, 2014). Selective knockout of the
p75 neurotrophin receptor from the cerebellar Purkinje cells of mice, results in autism-like behaviors
including diminished social interaction, a lack of interest in novel environments, in addition to a
decrease in the complexity of the dendritic arborization of their cerebellar Purkinje cells (Lotta et al.,
2014). When it comes to anxiety related disorders, there is conflicting information regarding p75. On
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one hand p75 knockout mice have been shown to display increased anxiety behavior and difficulties
recovering from stress compared to wild-types, with altered cholinergic transmission both at baseline
and in response to acute stress (Martinowich et al., 2012). On the other hand, there is evidence to
show that p75 knockout mice show markedly reduced anxiety levels, despite having increased fear
memory compared to wild-type controls (Olsen et al., 2013). Furthermore, p75 knockout mice were
found not to have altered anxiety-like behavior compared to wild-types in the elevated-plus maze,
light-dark, hole-board, T-maze or forced swim tests, however in a test for despair and depression-like
behaviors the knockout mice displayed increased mobility in the tail-suspension test compared to the
wild-type controls (Catts et al., 2008). Considering that p75 is more highly expressed in the
developing brain compared to the adult brain, where its expression is limited to certain neuronal
subpopulations (Shao et al., 2005), examination of TROY in the central nervous system in relation to
schizophrenia and other psychiatric disorders is warranted. Since TROY is a major partner of the
Lingo-1/NgR/TROY complex, and considering the significant upregulation reported in the CA1, with
no change in the CA3 of schizophrenia patients (Fernandez-Enright et al., 2014), additional
mechanisms may be involved in the regulation of this protein which will need to be further
investigated. Furthermore, a significant downregulation of TROY gene expression was found in the
fibroblasts of major depressive disorder patients compared to matched healthy controls (Garbett et al.,
2014), further implicating the Lingo-1/NgR/TROY complex in a wider variety of neuropsychiatric
disorders.
Previous studies have shown that WNK1 is a negative regulator of cell growth via phosphorylation of
the PI3-K/Akt signaling pathway (Jiang et al., 2005), and its overexpression was shown to be a
negative regulator of Nogo-induced inhibition of neurite extension and RhoA (Zhang et al., 2009).
WNK1 protein expression was found to be elevated in schizophrenia compared to control brains
within the CA1, but not CA3 or DLPFC in schizophrenia compared to controls (Fernandez-Enright et
al., 2014). This result was supported by previous literature reporting a consistent upregulation of
WNK1 gene expression in DLPFC post-mortem tissue from schizophrenia sufferers compared to
controls (Maycox et al., 2009). Interestingly, overexpression of WNK1 has also been reported to
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significantly reduce the interaction between endogenous WNK1 and Lingo-1, suggesting that it may
serve as a binding platform for Lingo-1, however its kinase activity may not be necessary for Lingo-1
signaling (Zhang et al., 2009). Furthermore, disruption of the WNK1 gene in mice leads to death of the
embryo at day 13 (Zambrowicz et al., 2003), suggesting an essential role of WNK1 in embryonic and
neural development, which is a critical period implicated in a number of neuropsychiatric disorders.
In support of this hypothesis, a young patient with autism spectrum disorder and a tendency for
anxiety, has been found to have a 1.5 Mb terminal deletion of the chromosomic region 12p13.33,
which encompasses the WNK1 gene in its entirety, in addition to 12 other genes (Silva et al., 2014).
Furthermore, Thevenon et. al. have shown that a number of patients with either de novo or inherited
12p13.33 microdeletions, present with not only a number of developmental abnormalities, but also
with a number of psychiatric disorders including autism spectrum disorder, attention-deficit
hyperactivity disorder, and anxiety (Thevenon et al., 2013). This is supported by a finding of a 6 Mb
deletion at 12p13.3 in 2 patients presenting with attention deficit hyperactivity disorder (one of whom
resided in a psychiatric center) encompassing around 50 genes including WNK1 (Madrigal et al.,
2012). Differential expression of gene transcripts has been found in military personnel suffering from
traumatic brain injury from blast exposure, who also suffer from post-traumatic stress disorder and
depression (Heinzelmann et al., 2014). WNK1 was found to be among the genes found to be
significantly upregulated in these military personnel compared to controls, further implicating WNK1
in a wider scope of psychiatric disorders.
Myelin transcription factor 1 (Myt1) and its highly conserved homolog, Myt1-like (Myt1l), are two
other well-characterized direct intracellular binding partners of Lingo-1. Although disruption of the
Myt1l gene has been reported in a Dutch schizophrenia population (Vrijenhoek et al., 2008), and
polymorphisms in the Myt1l gene have been recently reported to be associated with schizophrenia in a
Chinese Han population, specifically in female schizophrenia subjects (Li et al., 2012), little else is
known about the implication of the Myt1 gene and protein in schizophrenia. Interestingly, the Myt1
gene has been predicted to regulate the expression of Neuregulin-1, an extensively studied
schizophrenia candidate gene, in schizophrenia patients (Law et al., 2006). Similar to the expression
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profile of Lingo-1, we have reported significantly higher levels of Myt1 protein in the DLPFC of
schizophrenia subjects compared to controls, but like Lingo-1, levels of Myt1 were not significantly
altered in the CA1 or CA3 hippocampal regions (Fernandez-Enright et al., 2014). Considering the role
of Lingo-1 and Myt1 in oligodendrocyte and myelin dysfunction, it was not surprising to find an
increase in levels of both these proteins in the DLPFC of schizophrenia patients. Furthermore, both
Myt1l and Myt1 genes have been further implicated in other neuropsychiatric disorders, including
autism through a microduplication at 2p25.3 engulfing 7 exons of the terminal portion of Myt1l
(Meyer et al., 2012) and depression through SNP association (Wang et al., 2010); additionally,
microduplications in the Myt1l gene have been identified as being present in 2% of childhood onset
schizophrenia subjects from the same cohort of children who also display 22q11 deletions (Lee et al.,
2012). Further to this, Myt1 has been implicated in mental retardation, through its subtelomeric
deletion on 20q (Kroepfl et al., 2008), autism spectrum disorder, through a 1.4 Mb copy number
variation gain at 20q13.33 encompassing the Myt1 gene in its entirety as well as 43 other genes
(Moessner et al., 2007), in addition to having a potential role in attention deficit hyperactivity
disorder, demonstrated thorough a genome-wide pathway analyses which identified the cdc25
pathway of which Myt1 is involved, as being a candidate causal pathway for attention deficit
hyperactivity disorder (Lee and Song, 2014).
As mentioned above in section 3.4, Lingo-1 is able to negatively regulate the EGFR/PI3-K/Akt
signaling pathway (Inoue et al., 2007), also involved in neuronal survival and axon regeneration
(Brunet et al., 2001). Since Lingo-1 can directly inhibit EGFR independently of EGF activation,
leading to inhibition of PI3-K/Akt signaling pathways (Inoue et al., 2007); a downregulation of EGFR
induced by Lingo-1’s inhibitory action may be partly involved in the regional specificity of Lingo-1
expression in the DLPFC we observed compared to hippocampus in schizophrenia brains (FernandezEnright et al., 2014). In the same post-mortem schizophrenia brain cohort, higher levels of EGFR
protein in the DLPFC (Brodmann area 46) but not hippocampal regions in schizophrenia versus
control brains have been reported (Swaminathan et al., 2013). In the context of schizophrenia
pathophysiology, we postulate that greater levels of EGFR in the DLPFC may play a role in Lingo-1
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upregulation observed in this region, leading to inhibition of PI3-K/Akt signaling pathways in
schizophrenia. Moreover, the EGFR/PI3-K/Akt signaling pathway has also been implicated in autism,
post-traumatic and psychosocial stress disorders, as well as depression through a number of genetic
and neurobiological studies. EGFR gene regulation was found to be significantly upregulated in the
same cohort of military personnel suffering blast traumatic brain injury, post-traumatic stress disorder
and depression as those who also had an upregulation of WNK1 (Heinzelmann et al., 2014).
Furthermore, both SNP and copy number variation studies have implicated the EGFR/PI3-K/Akt
signaling pathway in autism spectrum disorders (Cuscó et al., 2009; Toyoda et al., 2007). On the
biochemical level, the evidence is a little more conflicting; as increased serum levels of EGF have
been reported in children with autism (İşeri et al., 2011), while in adults with high-functioning autism,
decreased levels of EGF have been found (Suzuki et al., 2007). This discrepancy suggests that EGF
plays a differential role in the progression of autism throughout development from childhood through
to adulthood. Significantly increased levels of EGF were also found in women exposed to prolonged
psychosocial stress (Åsberg et al., 2009). This is supported by a rodent study which found that Akt
signaling is significantly increased in the ventral tegmental area in response to stressful stimuli using a
social defeat paradigm (Krishnan et al., 2008).
In addition TrkB, another Lingo-1 binding partner, has been implicated in the pathophysiology of
several psychiatric disorders including drug addiction, schizophrenia, anxiety and bipolar disorders,
anorexia nervosa and suicide ideation (Gupta et al., 2013). Levels of TrkB mRNA were reported to be
decreased in the prefrontal cortex from individuals with suicide ideation (Dwivedi et al., 2003) and in
the hippocampus of patients suffering from schizophrenia and/or mood disorders (Iritani et al., 2003;
Thompson Ray et al., 2011) compared to healthy controls. Mutations in TrkB have also been linked to
anxiety disorders (Ernst et al., 2011) as well as susceptibility for nicotine (Beuten et al., 2007) and
alcohol addiction (Xu et al., 2007). Considering the antagonist effect of Lingo-1 on TrkB receptorphosphorylation (Fu et al., 2010), Lingo-1 may play a role in the disturbances of TrkB observed in a
range of psychiatric disorders, thus emphasizing the importance to further characterize the
relationship between Lingo-1 and its known and yet to be discovered signaling partners.
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6. Conclusions and Future Directions
Little is known about Lingo-1, and it is probably involved in many more neurological disorders that
we are not yet aware of due to its large range and wide reaching interactions with a variety of proteins
within the central nervous system. We have provided a large body of evidence demonstrating that
Lingo-1 signaling pathways are implicated in a wide range of central nervous system neurological
disorders including spinal cord injury, traumatic brain injury and multiple sclerosis; in addition to
Parkinson’s disease, essential tremor, Alzheimer’s disease, epilepsy and glaucoma. Furthermore, we
have provided the first report implicating Lingo-1 and its signaling partner proteins in the
schizophrenia pathophysiology, and provided sufficient evidence further implicating Lingo-1
signaling partners in the pathology of a number of neuropsychiatric disorders including autism
spectrum disorder, depression, attention-deficit hyperactivity disorder, anxiety, drug addiction and
post-traumatic stress disorder. Due to the role of the many Lingo-1 pathways as a negative regulator
of myelination and neurite outgrowth, and considering the implication of both of these central
processes in cognitive performance, antagonists of Lingo-1 appear to be a new potential candidate for
the treatment of a number of neurological and psychiatric disorders.
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Figure 1: Schematic representation of Lingo-1 signaling pathways implicated in neurological
and psychiatric disorders. Oligodendrocyte bound, myelin associated inhibitory proteins - myelin
associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp) and neurite outgrowth
inhibitor (Nogo-A) bind to the Nogo Receptor (NgR) with high affinity to inhibit neurite outgrowth
and myelination processes. NgR lacks a transmembrane domain and requires either the p75
neurotrophin receptor (p75) or TNF receptor orphan Y (TROY) co-receptors, in addition to Lingo-1 to
transduce its inhibitory signals. A number of other transmembrane proteins interacting with Lingo-1
on neurons are also implicated in a wide range of neurological disorders. These include: the epidermal
growth factor receptor (EGFR) along with its ligand epidermal growth factor (EGF), brain-derived
neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase B (TrkB), amyloid
precursor protein (APP), receptor tyrosine-protein kinase erbB-2 (ErbB2), and tropomyosin receptor
kinase A (TrkA) with its ligand nerve growth factor (NGF). These transmembrane protein-protein
interactions with Lingo-1 result in the activation of a number of downstream signaling proteins which
are further implicated in numerous neurological and psychiatric disorders; these include WNK lysine
deficient protein kinase 1 (WNK1), mitogen activated protein kinase 2/3 (MEK2/3), extracellular
signal reduced kinase 5 (ERK5), ras homolog gene family, member A (RhoA), phosphatidylinositide
3-kinase (PI3-K), protein kinase B (PKB, also known as Akt), and finally myelin transcription factor
1 (Myt1) and its homolog myelin transcription factor 1-like (Myt1l).
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Evidence for the involvement of Lingo-1 signaling and/or Lingo-1 binding proteins in neurodegenerative and neuropsychiatric disorders.
Disease

Protein(s)

Species/Model/Cell Line

Study Details

Findings

Reference

Alzheimer’s
Disease

APP, Lingo-1

Mouse, CD1

Mice underwent time-controlled transcardiac
perfusion cross-linking (tcTPC) following
anesthesia.

Novel interactions between Lingo-1 and APP
were found in the interactome map. This was
validated and confirmed by a series of coimmunoprecipitation experiments using
antibodies directed at APP or Lingo-1.

Bai Y. et. al. 2008

Interactome maps for APP were obtained by
immunoprecipitation and two-dimensional
liquid chromatography and mass
spectrometry.

Alzheimer’s
Disease

APP, Lingo-1

Chinese Hamster Ovary
(CHO) cells

CHO cells at 90% confluence were transfected
with APP695 and Lingo-1 constructs.
HA-tagged Lingo-1, and APP constructs were
co-immunoprecipitated

In situ hybridization studies showed that
Lingo-1 and APP are co-localized in the
mouse brain, with pronounced staining of
CA1 to CA3 hippocampal neurons.
APP was co-immunoprecipitated with Lingo-1
constructs that were lacking either the LRR
domain or the cytoplasmic domain of Lingo-1.

Stein T, and
Walmsley AR.
2012

Co-immunoprecipitation failed with a Lingo-1
construct comprising only the transmembrane
and cytoplasmic domain.
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Disease

Protein(s)

Species/Model/Cell Line

Study Details

Findings

Reference

The APP interaction with Lingo-1 occurs
within the Lingo-1 ectodomain, but does not
require the LRRs.
Alzheimer’s
Disease

EGFR

Drosophila, Aβ42 transgenic
flies
Mouse, APP/PS1 double
transgenic mice
[strain: B6C3Tg(APPswe.PSEN1dE9)
85Dbo/J]

Flies underwent a Pavlovian olfactory
associative immediate memory conditioning
assay, both before and after being treated with
EGFR inhibiting drugs Gefitinib and
Erlotinib.
Mice underwent a 7 day pretesting treatment
with Gefitinib before being subjected to the
Morris water maze task for 9 days.
Phospho-EGFR levels were assessed in the
hippocampus of the mice using western
blotting.

Alzheimer’s
Disease and
Spinal Cord
Injury

NgR, BDNF

Rat, Sprague-Dawley and
spontaneously hypertensive
rats (SHR)

Kainic acid (10 mg/kg i.p.) was administered
to Sprague-Dawley rats. Rats were decapitated
and brains removed and frozen at different
time points post injection for in situ
hybridization or autoradiography analysis.
SHR rats were given either unlimited access
or no access to running wheels, and were
decapitated at different time points after being
given access to running wheels.

Co-expression of EGFR in Aβ42-expressing
Drosophila exacerbated memory loss; while
inhibition of EGFR activity prevented
memory loss in Aβ42-expressing Drosophila.

Wang L. et. al.
2012

Treatment with Gefitinib completely
recovered impaired memory in the APP/PS1
double transgenic mice.
Phospho-EGFR was elevated in the
hippocampus of APP/PS1 double transgenic
mice, and could be suppressed by treatment
with Gefitinib.
Kainic acid injections resulted in strong
downregulation of NgR and strong
upregulation of BDNF mRNA in dentate
gyrus, hippocampus and neocortex.

Josephson A. et.
al. 2003

Running on wheels for 3 and 7 days resulted
in a significant downregulation of NgR mRNA
in the cortex, hippocampus and dentate gyrus.
No robust regulation of NgR was observed in
the spinal cord following spinal cord injury.

Spinal cord weight drop injuries were
performed on Sprague-Dawley rats; spinal
cords were collected at different time points
after injury.
Alzheimer’s
Disease

NgR

Human post-mortem brains
from Alzheimer’s Disease
subjects

Hippocampal samples were collected from 10
post-mortem female Alzheimer’s brains and
10 age-matched non-demented female brains.

NgR immunoreactivity was present in more
than 50% of the pyramidal layer cells of the
CA1 to CA4 subfields of the hippocampus.

Immunohistochemistry and double-labeling

No significant difference in the number of

Zhu H-Y. et. al.
2007
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Disease

Protein(s)

Species/Model/Cell Line

Study Details

Findings

immunofluorescence were used to investigate
the expression of NgR in the hippocampus of
Alzheimer’s Disease compared to control
brains.

immunopositive cells in the CA1 to CA4
regions was observed between Alzheimer’s
and control subjects.

Reference

A higher ratio of immunopositive cells to the
total number of pyramidal cells was observed
in the CA1 and CA2 hippocampal regions in
Alzheimer’s brains compared to control
brains.
Alzheimer’s
Disease

NgR, Nogo-A, APP

Human post-mortem brains
from Alzheimer’s Disease
subjects
Mouse, APPswe/PSEN1(ΔE9) double transgenic
mouse
Human Embryonic Kidney
HEK-293T cells
APPswe-N2A
neuroblastoma cells

Histological analysis of Nogo-A and NgR
immunoreactivity was performed in postmortem sections from the hippocampus and
Brodmann’s area 20/36 from 6 Alzheimer’s
brains and 6 control brains.
NgR localization was assessed in a transgenic
mouse model of Alzheimer’s disease.

Nogo-A and NgR are mislocalized in
Alzheimer’s brain samples. Neither NgR nor
Nogo-A co-localize with neurofibrillary
tangles or dystrophic neurites. Results
confirmed in transgenic mouse model.

Immunoprecipitation studies were performed
using the HEK-293T cells to determine
interactions between Nogo-A and NgR with
APP.

Overexpression of NgR decreases Aβ
production in N2A neuroblastoma culture.

Western blotting was used to examine
expression of endogenous NgR and Aβ
production in the N2A cell line.
APPswe/PSEN-1(ΔE9) double transgenic mice
were bred with NgR null mice to examine the
effect of the NgR/ APP interaction in vivo.
APPswe/PSEN-1(ΔE9) double transgenic mice
were treated with soluble NgR(310)ecto-Fc
protein to increase NgR APP interactions in
vivo.
Alzheimer’s
Disease

Nogo-A, OMgp,
MAG, NgR, Lingo1, TROY

Rat, Fisher 344

In situ hybridization was used to examine
mRNA levels of Nogo-A, OMgp, MAG, NgR,
Lingo-1 and TROY in the cortex and
hippocampus and young (4 months), middle

Park JH. et. al.
2006

APP is physically associated with NgR.

Targeted disruption of NgR expression
increases transgenic mouse Aβ levels, Aβ
plaque deposition and dystrophic neurites.
Infusion of a soluble NgR fragment reduces
Aβ levels, amyloid plaque deposits and
dystrophic neurites in a transgenic
Alzheimer’s disease mouse model.

No alterations in levels of NgR, Lingo-1,
TROY, OMgp or MAG were observed.

Trifunovski A. et.
al. 2006

Nogo-A was significantly decreased in the
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Disease
Alzheimer’s
Disease

Protein(s)
p75

Species/Model/Cell Line
Human post-mortem brains
from Alzheimer’s Disease
subjects

Study Details

Findings

aged (16 months) and old (24 months) rats.

hippocampus of the aged rats.

Expression of p75 was examined by
immunocytochemistry in the hippocampus
taken from the level of the lateral geniculate
body from 10 female Alzheimer’s Disease
subjects compared to 10 non-demented
controls.

Increased intensity of p75 immunoreactivity in
cell bodies and processed in the CA1 and CA2
of Alzheimer’s subjects compared to controls.

Reference
Hu X-Y. et. al.
2002

Increases in the ratio of p75 expressing
neurons to thionin (Nissl) stained neurons in
CA1 and CA2 of Alzheimer’s compared to
controls.
Large proportion of p75 expressing cells colocalized with Alz-50 (recognizes tau protein)
in CA1 and CA2 regions in Alzheimer’s
Disease subjects.

Autism

BDNF, TrkB, PI3K, Akt, mTOR, p75

Human post-mortem brains
from autism subjects
Rat, Valproic acid (VPA) –
induced rat model of autism

Protein levels were examined by western blot
in the fusiform gyrus of 11 autism and 13
control subjects and in the lateral temporal
neocortices of VPA rats and control rats.

Decreased TrkB, PI3K, Akt, mTOR and
phospho-mTOR protein levels in autism
compare to controls.

Fahnestock M,
and Nicolini C.
2014

Trending increase in truncated TrkB and p75
protein levels in autism compare to controls.
Similar results observed in VPA rats.

Autism

EGF

Human

Blood serum levels of EGF were examined by
sandwich ELISA in 27 autistic children and 28
age-matched controls (age 2-11 years)

Increased levels of EGF serum levels in
autistic children compared to controls.

İşeri E. et. al.
2011

Autism

EGF

Human, Japanese

Blood serum levels of EGF were examined by
ELISA in 17 male autistic subjects and 18
age-matched control subjects (aged 19-28
years).

Decreased serum levels of EGF in highfunctioning autism subjects compared to
controls.

Suzuki K. et. al.
2007

Autism

EGF

Human, Caucasian

Genetic association study using 252 White trio
families with a male offspring scored for
autism. Hispanic and Latino families were

A significant haplotypic association between
EGF gene and autism.

Toyoda T. et. al.
2007
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Disease

Autism

Autism

Protein(s)

Lingo-1

Myt1l

Species/Model/Cell Line

Human

Human

Study Details

Findings

excluded.

The rs4698803 and rs6533485 SNPs showed a
tendency towards an association with autism.

Genetic screening for copy number variants
across 15q24 was performed on 173 unrelated
subjects with autism spectrum disorder.
Additionally 1336 subjects with autism
spectrum disorder from 785 families were also
screened.
Results were confirmed by array comparative
genomic hybridization and quantitative PCR.

An atypical de novo deletion of 3.06 Mb in
15q23-24.1 was discovered in a boy with
autism. He shared many features with the
other 13 subjects with 15q24 microdeletion
syndrome that have been described to date.

Subjects were male half-siblings born to a
common mother by different fathers. Both
subjects score well above the cut-off for
autism on the Autism Diagnostic InterviewRevised (ADI-R).

Fluorescence in situ hybridization revealed
evidence for duplication in both affected halfbrothers.

The 2p25.3 duplication was identified in both
male siblings using an Affymetrix 10K SNP
microarray.

Autism

p75

Mouse, Purkinje cellselective p75 knockout mice
(Cre-loxP mice)

Reference

McInnes LA. et.
al. 2010

Deletions in 15q24 represent rare causes of
autism spectrum disorder.
Meyer KJ. et. al.
2012

Their mother tested positive for duplication of
33-40% of the fluorescence in situ
hybridization probes, revealing that she was
mosaic in her lymphoblasts for the
duplication.

Duplication of 2p25.3 was confirmed using
fluorescence in situ hybridization, and
Affymetrix 6.0 SNP arrays were used to more
precisely delineate the duplication
breakpoints.

Affymetrix 6.0 revealed that the 2p25.3
duplication was approx. 281 kb and that only
63 kb of the Myt1l terminus (containing 7
exons) was duplicated.

Immunohistochemistry was used to examine
quantitative microanatomy of the Purkinje
cells in the mice by genotype.

Cre-loxP mice exhibit complete knockout of
p75 in approx. 50% of their cerebellar
Purkinje cells.

Locomotor activity and social interaction were
assessed.

Cre-loxP mice display decreased
allogrooming, socialization and fighting with
other mice.

Lotta LT. et. al.
2014

Cre-loxP mice display decreased nonambulatory exploration of their environment
than wild types; and display increased
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Species/Model/Cell Line

Study Details

Findings

Reference

jumping behavior compared to wild-types.
Autism

PI3-K

Human, Caucasian

A comparative genomic hybridization array
was performed on a cohort of 96 Spanish
patients with idiopathic autism spectrum
disorder.

238 copy number variations were detected,
and of these, 13 were present specifically in
the autistic population (i.e. 12 out of the 96
individuals)

Cuscó I. et. al.
2009

Autism

WNK1

Human

An 8-year old boy of European origin
presented for evaluation of
neurodevelopmental delay. G-banded
chromosome analysis was performed on
peripheral blood lymphocytes. Array
comparative genomic hybridization was
performed on DNA extracted from peripheral
blood using a whole-genome, bacterial
artificial chromosome-based microarray.

Comparative genomic hybridization revealed
a 1.5 Mb terminal deletion at 12p13.33,
encompassing 13 different genes: B4GALNT3,
CCDC77, ERC1, FBXL14, IQSEC3, KDM5A,
LINC00942, LOC574538, NINJ2, RAD52,
SLC6A12, SLC6A13 and WNK1.

Silva IMW. et. al.
2014

Autism,
Attention
Deficit
Hyperactivity
Disorder and
Anxiety

WNK1

Human

A genetic study was performed on a series of
9 patients with 12p subtelomeric deletions,
including 2 familial cases with severs speech
sound disorders.

Subjects with either inherited or de novo
12p13.33 microdeletions present with
developmental abnormalities, in addition to
psychiatric disorders including autism
spectrum disorder, attention-deficit
hyperactivity disorder and anxiety.

Thevenon J. et. al.
2013

Essential
Tremor

Lingo-1

A meta-analysis was conducted on 11
association studies between Lingo-1
rs9652490 (3972 cases vs. 20714 controls),
and 7 association studies between Lingo-1
rs11856808 (2076 cases vs. 18792 controls)
and their risk for essential tremor.

There is a significant relationship between
Lingo-1 rs11856808 and essential tremor and
familial essential tremor.

Jiménez-Jiménez
FJ. et. al. 2012

Post-mortem tissue was obtained from
essential tremor patients and age-matched
controls.

Western blotting showed that Lingo-1 protein
was significantly increased in the cerebellar
cortex of essential tremor brains compared to

Essential
Tremor

The Human Genome CGH Microarray 44,
105, 180 or 244K from Agilent Technologies
was utilized for analysis and fluorescence in
situ hybridization and quantitative PCR were
used to confirm results.

Lingo-1

Human

Human post-mortem brains
from essential tremor
subjects

The Lingo-1 rs9652490 polymorphism was
only related to a familial risk for essential
tremor.
Kuo S-H. et. al.
2013
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Western blotting (using10 essential tremor
cases and 11 controls) and
immunohistochemistry (11 essential tremor
and 12 controls) were used to examine ingo-1
protein in essential tremor compared to
control brains.

Essential
Tremor

Essential
Tremor and
Parkinson’s
Disease

Lingo-1

Lingo-1

Human, Caucasian

Human, Caucasian

Findings

Reference

controls; however levels were similar in the
occipital cortex.
Immunohistochemistry revealed that Lingo-1
was enriched in the distal axonal processes of
basket cells, forming a pinceau structure
around the Purkinje cell axon initial segment.

Genome-wide association study was
conducted on Icelandic subjects with essential
tremor.

rs9652490 and rs11856808 SNPs were both
found to be significantly associated with
essential tremor.

Stefansson H. et.
al. 2009

Illumina HumanHap300 and HumanCNV370
chips were used.

Only the rs9652490 SNP was found to be
significant at the genome-wide level.

The cohort from this study included: 356
essential tremor patients from North America,
426 Parkinson’s disease patients form North
America, 618 Parkinson’s disease patients
from Norway; in addition to 428 controls from
North America and 602 controls from
Norway. All subjects were of Caucasian
descent.

There was a significant association between
the Lingo-1 SNP rs9652490 and both essential
tremor and Parkinson’s disease.

Vilariño-Güell C.,
Ross OA. et. al.
2010

Sequencing revealed 6 novel coding variants
in Lingo-1 (S4C, V107M, A277T, R423R,
G537A, and D610D), in addition to 5 known
polymorphisms (rs2271398, rs2271397,
rs2271396, rs3743481, and rs61737308).

Vilariño-Güell C.,
Wider C. et. al.
2010

Genotyping was performed using a TaqMan
probe on an ABI7900.
Essential
Tremor and
Parkinson’s
Disease

Lingo-1

Human, Caucasian

A total of 1247 essential tremor patients, 633
Parkinson’s disease patients, and 642 control
subjects were used in this study. All subjects
were Caucasian and from North America.
Genomic DNA was extracted from peripheral
blood lymphocytes and Lingo-1 and Lingo-2
genes were sequenced in 95 essential tremor
and 96 Parkinson’s disease patients (randomly
selected).

The Lingo-1 SNPs S4C, A277T, R423R,
G537A and D610D were observed exclusively
in cases (either essential tremor or both
essential tremor and Parkinson’s disease) and
not in controls.

Haplotype-tagging SNPs identified by
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sequencing were genotyped using a Sequenom
MassArray iPLEX platform.

Associations with essential tremor were also
observed for Lingo-1 SNPs rs4886887,
rs3144, rs8028808 and rs12905478; with
rs4883887 and rs3144 being driven by the
minor alleles.

Reference

The Lingo-1 SNP rs907396 was associated
with a 5-year younger mean age of onset of
essential tremor.
Glaucoma

Lingo-1, RhoA,
PI3-K, Akt

Rat, Sprague-Dawley

An experimental ocular hypertension model in
female rats was used.

Lingo-1 was expressed in RGCs and upregulated after intraocular pressure elevation.

Lingo-1 expression in retinas was investigated
using immunohistochemistry and western
blotting.

Blocking Lingo-1 using Lingo-1-Fc,
significantly reduced RGC loss both 2 and 4
weeks after ocular hypertension and promoted
RGC survival after optic nerve transection.

Soluble Lingo-1 (Lingo-1-Fc) and anti-Lingo1 antibody (mAb 1A7) were injected into
vitreous body to examine effects of Lingo-1
antagonism on RGC survival after ocular
hypertension and optic nerve transection.
Glaucoma

Lingo-1, BDNF,
TrkB

Rat, Sprague-Dawley

Fu Q-L. et. al.
2008

Lingo-1-Fc and mAb 1A7 treatment blocked
the RhoA pathway and promoted Akt
activation.

Experimental ocular hypertension model in
rats was used to examine whether BDNF
combined with Lingo-1 antagonists can
promote long-term RGC survival after ocular
hypertension.

BDNF alone shows slight neuroprotection to
RGCs 4 weeks after ocular hypertension.

Immunohistochemistry and western blotting
were used to assess TrkB and Lingo-1
expression.

Lingo-1 is co-expressed with BDNF receptor
TrkB in the RGCs

Fu Q-L. et. al.
2009

Combined BDNF and Lingo-1-Fc treatment
prevents RGC death in the same condition.

BDNF combined with Lingo-1-Fc activated
more TrkB in the injured retina compared to
BDNF alone.
Glaucoma

Lingo-1, NgR,
Myocilin

Mouse, Myocilin-null mice
(Myoc-null mice)

Myocilin-null mice were compared to wild
type mice in all experiments.

Myocilin is expressed and secreted by optic
nerve astrocytes.

Kwon HS. et. al.
2014
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Quantitative PCR, immunoprecipitation,
western blotting, immunohistochemistry and
co-immunoprecipitation experiments were
used to examine the role of Myocilin in the
optic nerve and the interaction of Myocilin
with the NgR/Lingo-1 complex.

Differentiation of optic nerve
oligodendrocytes is delayed in Myocilin-null
mice.

Reference

Optic nerves of Myocilin-null mice contain
reduced levels of MBP, myelin proteolipid
protein and 2’3’-cyclic nucleotide 3’phosphodiesterase compared to wild types.
Myocilin-null mice have reduced myelin
sheath thickness on optic nerve axons
compared to wild types.
Myocilin stimulates oligodendrocyte
differentiation through the NgR/Lingo-1
receptor complex.
Myocilin interacts physically with Lingo-1
and may be considered to be a Lingo-1 ligand.

Glaucoma

Lingo-1, TrkB,
BDNF

Rat, Sprague-Dawley
Human Embryonic Kidney
HEK-293T cells
overexpressing both Lingo-1
and TrkB

Adult female Sprague-Dawley rats underwent
a laser eye procedure to induce unilateral
ocular hypertension.

Lingo-1 forms a receptor complex with TrkB
and negatively regulates its activation in the
retina after ocular hypertension injury.

Lingo-1-Fc or 1A7 (2 μg in 2μL PBS) were
administered intravitreally to the rats on Day
0, then anti-BDNF (1 μg/μL) was injected into
the experimental eye on Day 0 (30 min after
1A7 or Lingo-1-Fc injection), then at 4, 7 and
10 days after laser treatment.

Lingo-1 antagonists 1A7 antibody or Lingo-1Fc treatment up-regulates phospho-TrkB
activation and leads to RGC survival after
ocular hypertension injury.

Immunoprecipitation studies using both HEK293T cells and cells from injured retinas were
conducted to assess if TrkB and Lingo-1 form
an interacting complex.

Fu Q-L. et. al.
2010

Treatment with an anti-BDNF antibody blocks
the neuronal protective effect of the Lingo-1
antagonists.
Blocking Lingo-1 promotes the activation of
TrkB after the induction of ocular
hypertension.

BDNF and TrkB expression levels in the rat
retinas were assessed by western blotting.
Retinal levels of BDNF were quantified by
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NgR was expressed in RGCs and was
upregulated after intraocular pressure
elevation.

Fu Q-L. et. al.
2011

ELISA.
BDNF-positive RGCs in the retina were
quantified by immunohistochemistry.
Glaucoma

NgR

Rat, Sprague-Dawley

Adult female Sprague-Dawley rats were
subjected to either a laser eye procedure to
induce unilateral ocular hypertension, or an
optic nerve transection procedure.
After the first laser eye procedure or
immediately following optic nerve transection,
an intravitreal injection of soluble sNgR-Fc
(2μg in 2 μL PBS) was given.
Rats were sacrificed at 5 days, 2 weeks or 4
weeks in the ocular hypertension model and at
1 week in the optic nerve transection model.
Rats in the 4 week group received treatments
once per week.

Treatment with soluble sNgR-Fc significantly
reduced RGC loss at both 2 and 4 weeks after
the induction of ocular hypertension.
sNgR-Fc treatment promoted RGC survival
after optic nerve transection.
sNgR-Fc attenuated synaptic degeneration at 5
days, 2 weeks and 4 weeks.

Expression of NgR in the normal and injured
rat retina was assessed by
immunohistochemistry.
The effect of sNgR-Fc on synaptic input after
the induction of ocular hypertension was
assessed by immunohistochemical analysis of
c-Fos expression.
Retinal NgR expression was measured by
western blotting.
Major
Depression

Myt1l

Human, Chinese Han

A total of 1139 major depressive patients (487
males and 652 females) and 1140 controls
(374 males and 766 females) were genotyped
from a Chinese Han population.

3 SNPs were found to have significant allelic
and genotypic associations with major
depressive disorder (rs3748989, rs3748988
and rs7592630).

8 tag SNPs were genotyped (rs1617213,

After correction by SNPSpD rs3748989

Wang T. et. al.
2010
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Human Fibroblasts
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rs6759709, rs6727410, rs11687068,
rs3748989, rs3748988, rs4305302 and
rs7592630), using the ABI 7900 DNA
detection system with Taq-Man probes from
Applied Biosystems.

retained genotypic and allelic significance,
and rs3748988 retained genotypic
significance.

Cultured dermal fibroblast samples from
patients with major depressive disorder and
matched controls were assayed for genomewide mRNA expression using an Agilent 2100
Bioanalyzer microarray assay. Results were
validated by quantitative PCR.

Fibroblasts from major depressive patients
showed a strong mRNA expression pattern
change in molecular pathways including cellto-cell communication, innate/adaptive
immunity, and cell proliferation.

Quantitative PCR was also used to assess over
1000 microRNA (miRNA) species.

Reference

Garbett KA. et. al.
2014

The same fibroblasts showed altered
expression of a distinct panel of 38 miRNAs.
TNFRSF19 mRNA is downregulated in
fibroblasts from major depressive disorder
patients compared to matched healthy
controls.

Megalencephaly

BDNF, TrkB,
Nogo-A, Lingo-1,
NgR, TROY,
OMgp

Mouse, BALB/cByJKv1.1mceph/mceph

BALB/cByJ-Kv1.1mceph/mceph (also known as
mceph/mceph) mice and wild type mice were
treated with carbamazepine (3.5 g/kg pellets)
from postnatal week 6 to 12. The expected
daily intake of carbamazepine was 0.5 g/kg
body weight per rat.
Levels of BDNF, TrkB, Nogo-A, Lingo-1,
NgR, TROY, and OMgp mRNA were assessed
by in situ hybridization in mceph/mceph mice
compared to wild types along with the effects
of carbamazepine treatment on mRNA levels.

BDNF mRNA was significantly increased in
the CA3, ventral cortex, amygdala and CA1 of
mceph/mceph mice compared to wild types.

Lavebratt C. et.
al. 2006

TrkB mRNA was significantly upregulated in
the dentate gyrus of mceph/mceph mice
compared to wild types.
Nogo-A mRNA hybridization was increased in
the CA3 of mceph/mceph mice compared to
wild types.
NgR mRNA was increased in the dentate
gyrus in mceph/mceph mice compared to wild
types.
Lingo-1 mRNA was increased in the CA3,
dentate gyrus, ventral cortex and amygdala in
mceph/mceph mice compared to wild types.
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TROY mRNA was decreased in the cortex,
dentate gyrus CA1 and ventral cortex of
mceph/mceph mice compared to wild types.
OMgp mRNA levels were upregulated in the
amygdala of mceph/mceph mice compared to
wild types.
Treatment with carbamazepine completely
normalized all of the dysregulations in the
expression of BDNF, Nogo-A, NgR, Lingo-1
and TROY mRNA in the mceph/mceph mice.
TrkB and OMgp levels were not normalized
by carbamazepine treatment.
Multiple
Sclerosis

Lingo-1

Mouse, myelin
oligodendrocyte
glycoprotein-induced
experimental autoimmune
encephalomyelitis (EAE)
mice; created from C57/BL6
mice

Lentiviral vectors encoding Lingo-1 short
hairpin RNA (LV/Lingo-1-shRNA) were
constructed to inhibit Lingo-1 expression.

Lingo-1 mRNA and protein expression was
higher in untreated EAE mice compared to
wild types at all time points examined.

EAE mice received intracerebroventricular
injections (5μL) of LV/Lingo-1shRNA into
both lateral ventricles over a 5 min time
period followed by an additional 2 min delay
to allow for diffusion before removal of the
cannula.

Lingo-1 mRNA and protein levels were
significantly downregulated by LV/Lingo-1shRNA treatment compared to the untreated
EAE mice.

Locomotor activity was assessed at different
time points (1, 3, 7, 14, 21 and 30 days after
injection).
Levels of myelination were examined by luxol
fast blue staining.
Lingo-1 mRNA and protein expression were
examined from cortical samples by real-time
PCR and western blotting respectively.
Multiple
Sclerosis

Lingo-1

Human, Caucasian

The cohort used for this study consisted of
293 unrelated Caucasian Spanish patients (203

Wang C-J. et. al.
2014

Locomotor activity scores were significantly
lower in the LV/Lingo-1-shRNA treated
groups than in the untreated mice.
Significant demyelination was observed in the
EAE mice compared to the wild type mice.
LV/Lingo-1-shRNA treatment resulted in
significantly higher myelination than the
untreated group, but myelination levels
remained lower than in the wild type mice.

Lingo-1 SNPs rs9652490 and rs11856808
were found not to have any significant allelic

García-Martín E.
et. al. 2013
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females and 90 males, average age 43.9±11.4)
and 318 healthy, unrelated controls (221
females and 97 males, average age 43.7±12.4),
matched for age and gender.

or genotypic associations with multiple
sclerosis.

Genomic DNA was obtained from peripheral
leukocytes and the Lingo-1 SNPs rs9652490
and rs11856808 were genotypes using
KASPar assays.
Multiple
Sclerosis

Lingo-1

Human

Two separate randomized, placebo-controlled
Phase 1 clinical trials were performed. Single
ascending doses (0.1 to 100 mg/kg) and
multiple ascending doses (0.3 to 100 mg/kg; 2
doses separated by 14 days) of BIIB033 or
placebo were administered intravenously to 64
healthy adult volunteers and 42 subjects with
relapsing-remitting or secondary progressive
multiple sclerosis respectively.

Reference

Allelic and genotypic frequencies were found
to be unrelated to the age of onset of multiple
sclerosis, gender and the clinical course of the
disease.

BIIB033 infusions were well tolerated.

Tran J. et. al.
2014

The frequency of adverse effects was similar
between BIIB033 and placebo; headache was
the most frequently reported adverse effect.
Doses at 10 mg/kg or higher resulted in
BIIB033 concentrations similar to or higher
than the concentration associated with 90% of
the maximum remyelination effect in rats.

Safety assessments included adverse event
monitoring, neurologic examinations,
conventional and non-conventional MRI,
EEG, optical coherence tomography, retinal
examinations and evoked potentials.
Serum and cerebrospinal fluid samples were
collected to measure BIIB033 concentrations.
Multiple
Sclerosis

Lingo-1

Rat, myelin oligodendrocyte
glycoprotein-induced
experimental autoimmune
encephalomyelitis (EAE)
rats

Myelin oligodendrocyte glycoprotein-induced
experimental autoimmune encephalomyelitis
(EAE) was induced in both mice and rats
(Lingo-1 knockout mice vs. wild type
C57BL6J mice, and Sprague-Dawley rats).

Mouse, Lingo-1 knockout

3 days after EAE induction, rats were treated
with either intrathecal injections of either an
isotype control antibody, or anti-Lingo-1 (185
mg/day for 2 weeks); or intraperitoneal

Lingo-1 knockout mice have an earlier onset
of myelination compared to wild-types.

Mi S. et. al. 2007

While both wild-type and Lingo-1 knockout
mice displayed EAE symptoms, the EAE
scores were significantly higher in Lingo-1
knockout mice.
Electron microscopy showed that lower EAE
scores reflect remyelination.
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injections of the same antibodies (8mg/kg
twice per week for 2 weeks).
Lingo-1 knockout and wild-type control mice
also underwent EAE induction.
All animals were perfused 30-36 days after
EAE induction and spinal cord tissues were
prepared for diffusion tensor imaging,
immunocytochemistry and electron
microscopy analysis to assess the levels of
de/re-myelination in the different treatment
groups.

Findings

Reference

Lingo-1 knockout EAE animals showed an
abundance of newly formed myelin sheaths,
and had more myelinated fibers overall
compared to wild-type EAE mice.
Blocking Lingo-1 function either by gene
knockout or though treatment with an antiLingo-1 antibody, promotes functional
recovery in the EAE model.
Functional recovery is correlated with
improved axonal integrity and axonal
myelination.
Demyelination in the spinal cord of antiLingo-1 treated EAE rats was five times lower
than in the control group.
More myelination and/or remyelinated axons
were found in anti-Lingo-1 treated rats.

Multiple
Sclerosis

Lingo-1, TROY,
p75, NgR

Human post-mortem brains
from multiple sclerosis
subjects

Post-mortem brain samples from the frontal
cerebral cortex or the cerebellar cortex were
obtained from autopsied brains from 5
multiple sclerosis patients and 10 non-multiple
sclerosis cases.
Immunoreactivity and protein expression
levels were assessed for both Lingo-1 and
TROY proteins by immunohistochemistry and
Lingo-1, TROY, p75 and NgR proteins by
western blot respectively.

Immunohistochemistry revealed that Lingo-1
and TROY are expressed in the cerebral
cortex, brainstem and spinal cord from both
multiple sclerosis and non-multiple sclerosis
brains; and that this expression is in neurons,
reactive astrocytes, and
macrophages/microglia, but not
oligodendrocytes.

Satoh J. et. al.
2007

Western blot revealed overall higher levels of
TROY expression in multiple sclerosis brains
compared to non-multiple sclerosis brains.,
whereas Lingo-1 levels were found to be
reduced in all multiple sclerosis cases.
Expression pattern of p75 was generally the
same as that of TROY, and NgR showed a
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trend for higher levels in the cerebellum vs.
lower levels in the cerebrum.
Multiple
Sclerosis

Lingo-1, RhoA

Primary cell culture, dorsal
root ganglion (DRG)
neurons from E14-17 Long
Evans rats

Primary dorsal root ganglion (DRG) cell
cultures of embryonic E14-17 Long Evans rats
were grown in vitro for testing with: Lingo-1Fc, dominant-negative (DN)-Lingo-1, fulllength (FL)-Lingo-1 or Lingo-1 RNAi.

RT-PCR in purified populations of CNS cells
showed Lingo-1 is expressed highly in
neurons, a low expression in
oligodendrocytes; however it is not expressed
in astrocytes.

The number of total and mature
oligodendrocytes was quantified by western
blot analysis and electron microscopy.

In situ hybridization and
immunohistochemistry in sections from adult
optic nerve tissue confirmed the expression of
Lingo-1 in oligodendrocytes.

Mi S. et. al. 2005

Rat, Long Evans
Mouse, Lingo-1 knockout

Myelinated axons in the 2-week-old cultures
were quantified by counting the number of
myelinated internode bundles that were
derived from single MBP+ oligodendrocytes.
Immunohistochemistry was used to examine
expression of O4, MBP, CNPase, and Lingo-1
in tissue sections from mice and in cell
cultures.
Lingo-1 expression was examined in rat optic
nerve sections by in situ hybridization.
mRNA extracted from rat brains was
subjected to RT-PCR to quantify Lingo-1
mRNA.
Oligodendrocyte progenitor cells were treated
for 2 days with Lingo-1-Fc or control-Fc.
RhoA-GTP and RhoA amounts were
quantified.
Expression levels of the myelin proteins MBP
and MAG in cells were determined by western
blotting.

RT-PCR showed that Lingo-1 RNAi infected
oligodendrocytes had reduced levels of
endogenous Lingo-1 expression. This
reduction in Lingo-1 resulted in more highly
differentiated and mature oligodendrocytes,
increased length of cell processes and more
abundant myelin sheath structures.
DN-Lingo-1 infected oligodendrocytes
showed increased differentiation and resulted
in a five-fold increase in the number of mature
oligodendrocytes; in addition to a five-fold
increase in the amount of MBP expressed.
Overexpression of FL-Lingo-1 inhibited
differentiation; the cells had less developed
processes and an 80% reduction in the number
of mature oligodendrocytes. Additionally,
these cells also displayed 90% lower amounts
of MBP expressed.
A2B5+ oligodendrocyte progenitors treated
with Lingo-1-Fc differentiated into mature
oligodendrocytes in a concentration dependent
manner. The treatment also resulted in
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DRG neuron and oligodendrocyte cultures
were grown for 4 weeks in the presence of
Lingo-1-Fc (10 μg/ml) or control-Fc.

oligodendrocytes with longer processes and
more abundant myelin sheaths.

Ultrastructural analysis of spinal cords from
Lingo-1 knockout mice and the DRG cultures
was performed using electron microscopy.

Reference

Treatment of oligodendrocytes with Lingo-1Fc, DN-Lingo-1 or Lingo-1 RNAi resulted in
reduced levels of RhoA.
Lingo-1-Fc and DN-Lingo-1 treatment on
oligodendrocyte and neuron co-cultures
resulted in concentration dependent robust
axonal myelination. MAG, MOG, OMgp,
CNPase and MBP were also upregulated.
Furthermore FL-Lingo-1 decreased MBP
expression by 50%.
Primary cell cultures from Lingo-1 knockout
mice have more highly differentiated and a
larger percentage of mature oligodendrocytes
than wild-type cultures.
Spinal cords from Lingo-1 knockout mice
contained more myelinated fibers than wildtype spinal cords.

Multiple
Sclerosis

Lingo-1

Rat, myelin oligodendrocyte
glycoprotein-induced
experimental autoimmune
encephalomyelitis (EAE)
rats
Rat, oligodendrocyte
cultures, dorsal root
ganglion (DRG) neuron
cultures, co-culture
myelination assays and
oligodendrocyte
differentiation assays
Rat, Sprague-Dawley

1A7 or isotype control antibody (4 μg) was
injected intravitreally into the right eye of
EAE rats from disease onset for 2 weeks.
Oligodendrocyte cultures, dorsal root ganglion
(DRG) neuron cultures, co-culture
myelination assays and oligodendrocyte
differentiation assays were prepared.
300 μm sections were taken from the brains of
PN2 mice at the junction of the corpus
callosum to the hippocampus. Sections were
cultured in serum containing either antiLingo-1 (10 μg/ml) or control antibody for 4
days.

Optic nerves of antibody treated EAE rats
showed evidence of extensive myelination
compared to rats treated with control
antibody; myelin sheaths of treated rats were
thinner than those in untreated rats, suggesting
that they were remyelinated.

Mi S. et. al. 2009

1A7 antibody treatment produced robust
myelination in co-cultures of DRG and OPCs
compared to treatment with the isotype
antibody control. Western blotting showed a
dose dependent increase in MBP expression in
the co-cultures treated with the 1A7 antibody.
Incubation of P2 forebrain slices with 1A7
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Sagittal cerebellar slices were taken from
PN10 rats and grown for 7 days before
treatment with 5 mg/ml
lysophosphatidylcholine (LPC) to induce
demyelination. Slices were then incubated
with 1A7 or control antibody (10 μg/ml) for 3
days, and remyelination was visualized by
MBP immunostaining.
Rats received direct injections of LPC into the
spinal cord, followed 3 days later by treatment
with 1A7 or control antibody (1.5 μg in 2 μl).
LPC-treated rat spinal cords were sectioned
and toluidine blue staining and electron
microscopy were used to assess levels of
remyelination versus demyelination.
Immunohistochemistry was used to visualize
myelination with anti-MBP, oligodendrocyte
precursor cells (OPCs) with anti-NKx2.2 and
Lingo-1 positive (Lingo-1+) OPCs with antiLingo-1 in the lesions of 1A7 antibody and
control treated rats.
Cuprizone treated mice received stereotaxic
injections of 1A7 of isotype control antibody
at weeks 2.5 and 3 of cuprizone feeding. Mice
were euthanized 4 and 6 weeks after antibody
injection.
Lingo-1 knockout and wild-type mice also
received cuprizone treatment for 4 weeks to
assess the number of myelinated axons.

Findings

Reference

for 4 days resulted in approximately 30-fold
increased staining of MBP-positive cells and
20-fold increase in myelinated axon clusters
distributed in the periventricular area and
cerebral cortex.
Exposure to 1A7 antibody for 3 days after
removal of LPC from P10 cerebellar slices
resulted in an extensive reorganization of the
MBP+ fibers which had previously been
punctuated and disorganized by the LPC.
Lingo-1 was strongly expressed in OPCs
compared with mature oligodendrocytes, and
increased numbers of Lingo-1+ cells were seen
in 7-day post-LPC spinal cord lesions. The
number of NKx2.2+ and Lingo-1+ cells was
also increased in the lesions. Toluidine blue
stained sections and electron microscopy
showed a three-fold increase in myelinated
fibers in 1A7-treated animals compared with
control animals.
1A7-treated lesions displayed less Lingo-1+
OPCs and more mature MBP+
oligodendrocytes than antibody controls;
treatment with Lingo-1 antagonists also
enhanced re-myelination in the LPC rat and
slice models.
Cuprizone treated mice that also received 1A7
treatment showed substantially more MBP
staining, indicative of increased myelin, than
control treated mice. This was confirmed by
ultrastructural analysis by electron
microscopy.
Lingo-1 knockout mice had significantly more
myelinated axon fibers after 4 weeks of
cuprizone treatment compared to wild-types.
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Multiple
Sclerosis

Nogo-A, NgR, p75,
APP

Human post-mortem brains
from multiple sclerosis
subjects

Post-mortem brain samples from the frontal
cerebral cortex or the cerebellar cortex were
obtained from autopsied brains from 4
multiple sclerosis patients, 6 non-multiple
sclerosis cases with
neurologic/neuropsychiatric disorders, and 6
neurologically normal cases.

Immunohistochemistry revealed a substantial
number (20%-60%) of surviving
oligodendrocytes and remaining myelin
sheaths in multiple sclerosis cases expressed
intense levels of Nogo-A. Adjacently stained
sections revealed that APP reactive axons
were hardly detectable in any case examined,
and that these axons did not co-localize with
Nogo-A expressing oligodendrocytes.

Satoh J-I. et. al.
2005

Immunoreactivity and protein expression
levels were assessed for Nogo-A, NgR, APP
and p75 proteins by immunohistochemistry
and Nogo-A and NgR proteins by western blot
respectively.

Immunohistochemistry also showed that a
large number (>60%) of astrocytes, microglia
and neurons have an intense immunoreactivity
for NgR.
p75 was most prominently expressed in the
nerve fibers of substantia gelatinosa in the
spinal cord, tractus solitaries in the brain stem
and the vascular wall of the cerebrum. p75
was not expressed on oligodendrocytes,
astrocytes or microglia/macrophages.

Multiple
Sclerosis

Nogo-A, NgR

Mouse, myelin
oligodendrocyte
glycoprotein-induced
experimental autoimmune
encephalomyelitis (EAE)
C57BL/6 mice

Myelin oligodendrocyte glycoprotein-induced
experimental autoimmune encephalomyelitis
(EAE) was induced in C57BL6J mice.
Mice were euthanized at 4 different time
points (Day 0 – naïve, Day 10 – preclinical,
Days 18-22 – acute, and Day 50 – chronic).
Nogo-A expression was examined by in situ
hybridization in the olfactory bulb, cortex,
piriform cortex, hippocampus, thalamus,
cerebellum, brain stem and spinal cord.
Nogo-A and NgR mRNA was quantified
using semiquantitative RT-PCR using RNA
extracted from both brain and spinal cord
tissues.

In situ hybridization and RT-PCR revealed
that Nogo-A expression is reduced at
preclinical and acute phases, followed by an
upregulation during the chronic phase.

Theotokis et.al.
2012

Nogo-A mRNA was expressed in neurons and
oligodendrocytes.
Immunohistochemistry and western blotting
showed that Nogo-A protein expression was
increased in the chronic phase and was
inversely correlated with axonal regeneration
and axonal injury.
Cortical NgR protein and mRNA levels were
increased in the chronic phase.
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CSPG-positive perineuronal nets surround
parvalbumin-positive inhibitory neurons,
leaving all other neurons unaffected.

McGee AW. et.
al. 2005

Nogo-A and NgR protein expression was
examined by immunohistochemistry and
western blotting analyses in brain and spinal
cord sections.
Double immunofluorescent labeling was
performed to identify the different types of
Nogo-A positive cells throughout the different
EAE time-points. Macrophages were double
stained with Nogo-A/Mac-3,
microglia/macrophages were stained with
Nogo-A/lectin, myelin was stained with
Nogo-A/CNPase, neurons were stained with
Nogo-A/NeuN, and astrocytes were stained
with Nogo-A/GFAP.
Optic Nerve
Regeneration

NgR

Mouse, NgR knockout mice

The abrupt loss of ocular dominance plasticity
at the end of the critical period, at which the
cerebral cortex is sensitive to experiencedependent plasticity, was examined in single
unit cortical recordings from anesthetized
mice.
Wisteria floribunda agglutinin-stained sections
of the visual cortex were examined to assess
the cellular site of chondroitin sulfate
proteoglycans (CSPGs).
Homogenates of visual cortex were analyzed
by western blotting for MBP, NgR, Nogo-A
and MAG.
Immunohistochemical layer-specific analysis
was used to assess MBP expression between
PN26 and PN60 in NgR knockout mice.
Electrophysiological responsiveness of the
binocular visual cortex was characterized in
NgR knockout mice exposed to unmodified
visual stimuli.

Myelin associated proteins including ligands
for NgR were easily detectable in the postnatal
visual cortex. The abundance of NgR ligands
Nogo-A and MAG was consistent in the visual
cortex over the time course of the critical
period, whereas NgR tends to increase
slightly. The total concentration of MBP
remained nearly constant; however layerspecific levels of intracortical myelin mature
considerably as the critical period ends.
The onset and distribution of cortical
myelination in NgR knockout mice is
indistinguishable from that of wild-type mice.
NgR and Nogo-A mutant mice are sensitive to
monocular deprivation after the critical period
compared to wild-types, as assessed by their
weighted ocular dominance (WOD) scores.
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Since WOD scores of NgR knockout mice
were indistinguishable from the wild-type
mice, visual system development and
immature cortical plasticity are normal in the
absence of NgR.
Physiological NgR signaling from myelinderived Nogo-A, MAG and OMgp consolidate
the neural circuitry established during
experience-dependent plasticity.
Overall, NgR knockout mice display normal
levels of plasticity during the critical period,
however it continues abnormally, such that
ocular dominance at 45 or 120 days postnatal
is subject to the same plasticity as at juvenile
ages.
Parkinson’s
Disease

Akt

Human post-mortem brains
from Parkinson’s disease
subjects

Frozen tissue from the midbrain and paraffinembedded sections of substantia nigra pas
compacta from 5 idiopathic Parkinson’s
disease cases and 5 controls (matched for age,
gender, post-mortem delay and tissue pH)
were obtained from the Netherlands Brain
Bank. Tissue was dissected using a
perpendicular cut to the brainstem at the level
of the superior colliculus.

Western blot of midbrain fractions from
Parkinson’s disease compared to control
brains showed reduced levels of both total and
active phosphoSer473-Akt in Parkinson’s
disease.
Immunofluorescence microscopy of the
substantia nigra pars compacta confirmed
these results.

Western blotting for Akt and phospho Ser473Akt was performed on fractions prepared from
midbrain tissue containing the substantia nigra
pas compacta.

Double immunofluorescence microscopy
showed that Akt and phosphoSer473-Akt are
expressed at high levels in tyrosine
hydroxylase immunopositive dopaminergic
neurons in the control human brain.

Immunofluorescent microscopy was also
performed for Akt and phosphoSer473-Akt in
addition to tyrosine hydroxylase.

Loss of these neurons in Parkinson’s disease
was accompanied by a marked decrease in Akt
and phosphoSer473-Akt.

Timmons S. et. al.
2009
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Parkinson’s
Disease

EGF

Rat, Hanover-Wistar (E14
primary cell cultures from
ventral mesencephalon)

E14 embryos were collected from pregnant
Hanover-Wistar rats and primary cells
collected from the ventral mesencephalon
floor were cultured.

Heparin-binding epidermal growth factor-like
growth factor (HB-EGF) is expressed in close
proximity to developing dopaminergic
neurons.

Farkas LM. et. al.
2002

Immunostaining on cultured cells was
performed to differentiate between nuclei of
proliferating cells, or glial cells from tyrosine
hydroxylase positive dopaminergic neurons.

HB-EGF promotes survival of midbrain
dopaminergic neurons.

Immunohistochemistry using anti-tyrosine
hydroxylase and anti-heparin-binding
epidermal growth factor-like growth factor
(HB-EGF) was performed.
Western blotting using anti-pTyr, antiERK(pT202/pY204), anti-Akt(pS473) and
anti-Tyr, was performed on ventral
mesencephalic cells that had been treated with
HB-EGF for 7 days.
Parkinson’s
Disease

EGF, EGFR, ErbB2

Human post-mortem brains
from Parkinson’s disease
subjects

Post-mortem samples were collected from the
prefrontal cortex (BA9) and putamen from 9
chronic Parkinson’s disease brains (4 male, 5
female) and 10 controls (6 male, 4 female).

Rat, Wistar
Male Wistar rats received intra-nigral
infusions of 6-hydroxydopamine (2 μL of 4
mg/mL) or saline under pentobarbital
anesthesia to induce dopaminergic lesions.
A second group of male Wistar rats received a
subcutaneous implantation of an osmotic
minipump filled with human recombinant
EGF (0.3 mg/mL) or saline, in addition to the
intra-nigral infusions. These rats were infused
continuously at a rate of 0.5 μL/h for 7 days.

HB-EGF mediates its neuroprotective effects
via astrocytes.
Endogenous HB-EGF contributes to the
survival of dopaminergic neurons.
Survival promoting effect of HB-EGF is
mediated via the EGFR/Akt and MAPK
signaling pathways.

Protein levels of EGF and tyrosine
hydroxylase were decreased in the prefrontal
cortex and striatum of patients.

Iwakura Y. et. al.
2005

Heparin-binding epidermal growth factor-like
growth factor (HB-EGF) and transforming
growth factor alpha (TGF-α) were not
significantly altered in either region.
EGR receptors (ErbB1, ErbB2 but not ErbB3
or ErbB4) were downregulated in the same
forebrain regions.
In the rats treated with nigral 6hydroxydopamine infusion to induce
dopaminergic lesions, the same results were
replicated.
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Enzyme immunoassays were performed on
collected brain tissues to determine growth
factor concentrations.

EGF and ErbB1 were reduced in the striatum
in the lesioned hemisphere compared to the
control hemisphere of the treated rats.

Protein levels of ErbB family members,
tyrosine hydroxylase and neuron-specific
enolase were determined by western blotting.

Subchronic supplementation of EGF in the
striatum of the Parkinson’s disease rat model
was able to locally prevent the dopaminergic
neurodegeneration as measured by tyrosine
hydroxylase immunoreactivity.

A meta-analysis from 12 case-control studies
was performed for the Lingo-1 SNP
rs9652490.

The meta-analysis showed an overall lack of
association of rs9652490 and Parkinson’s
disease.

A total of 6053 Parkinson’s disease cases and
5997 controls, across 4 studies in Asians and 8
studies in non-Asians were included in the
meta-analysis.

Separate analysis in subjects of Asian origin
of non-Asian origin also failed to show any
ethnic dependent association.

The Lingo-1 SNP rs9652490 was examined in
two independent case-control Chinese
populations involving a total of 1305 subjects
(649 Parkinson’s disease patients and 656
controls) from Taiwan and Singapore.

There were no significant genotypic or allelic
associations with the risk of Parkinson’s
disease in either of the two case-control
populations, nor were there any associations in
the pooled analysis.

The cohort from Taiwan (421 Parkinson’s
disease patients and 411 controls) was
genotyped using TaqMan Assays.

Meta-analysis including all published data to
date and the present study’s data failed to
demonstrate any modulatory role of the
Lingo-1 rs9652490 SNP in Parkinson’s
disease.

The cohort from Singapore (228 Parkinson’s
disease patients and 245 controls) was
genotyped using the Sequenom MassArray
system.
Parkinson’s
Disease

Lingo-1

Human, Caucasian

The Lingo-1 SNP rs9652490 was examined in
a cohort of 162 Polish Parkinson’s disease
patients (73 females and 89 males) and 177
controls (81 females and 96 males). All
subjects were of Caucasian origin.

Genotyping frequencies were similar in both
Parkinson’s disease patients and controls.

Reference

Wu Y. et. al. 2012

Wu Y-R. et. al.
2011

Białecka M. et. al.
2010

There were no significant differences in either
genotypic or allelic frequencies between cases
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and controls.
Genotyping was performed using the
Sequenom MassArray system

Parkinson’s
Disease

Lingo-1, EGFR,
Akt

Human post-mortem brains
from Parkinson’s disease
subjects
Rat, Sprague-Dawley
Mouse, Lingo-1 knockout
Mouse, C57BL/6

In situ hybridization and semi-quantitative
RT-PCR was used to assess levels of Lingo-1
in the post-mortem human substantia nigra of
Parkinson’s disease brains compared to age
matched controls.
Lingo-1 levels were assesses by in situ
hybridization and/or immunohistochemistry
on adult rat brains and rat primary in vitro
embryonic cultures from E15 rat brains.
The function of Lingo-1 in dopaminergic
neurons was studied in vitro in the presence of
Lingo-1 antagonists: Lingo-1-Fc protein, an
anti-Lingo-1 antibody (1A7) or a dominantnegative (DN) form of Lingo-1.
Stereotaxic striatal injections of 6hydroxydopamine (6-OHDA) and
intraperitoneal injections of N-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)
were used to create neurotoxin induced
experimental models of Parkinson’s disease in
Lingo-1 knockout and wild-type mice.
Lingo-1-Fc protein (6.5 μg/μL; total 2 μL) or
the Fc-fragment (as a control) was injected
unilaterally into the striatum of C57BL/6
mice. Seven days after treatment, mice
received intraperitoneal injections of MPTP.
Mice were euthanized 1 week later.

When the Parkinson’s disease group was split
into early onset and late onset Parkinson’s
disease, there were still no significant
differences in genotypic or allelic frequencies
between case and control groups.
Lingo-1 mRNA levels were found to be
significantly higher in the substantia nigra of
Parkinson’s disease patients than controls.

Inoue H. et. al.
2007

In the ventral midbrain of normal adult rats,
Lingo-1 mRNA was expressed in many
neuronal types, and was co-localized with
tyrosine hydroxylase positive dopaminergic
neurons.
In primary ventral midbrain cultures, Lingo-1
protein was also found to be present in
tyrosine hydroxylase neurons. In the cells
treated with DN-Lingo-1, 1A7 antibody or
Lingo-1-Fc, dopaminergic neurons had longer
neurites than control cultures. Additionally,
DN-Lingo-1 transduction also resulted in
increased levels of p-Akt and elevated levels
of EGFR.
Motor asymmetry was significantly lower in
6-OHDA treated Lingo-1 knockout compared
to wild-type mice.
6-OHDA produced a significant loss of
tyrosine hydroxylase neurons in the substantia
nigra pars compacta of both wild-type and
knockout mice; while MPTP resulted in a
lower number of tyrosine hydroxylase neurons
in the wild-type compared to Lingo-1
knockout mice.

23

Disease

Protein(s)

Species/Model/Cell Line

Study Details

Findings

EGFR and Lingo-1 interactions were
examined in cultured cells and wild-type or
Lingo-1 knockout ventral midbrain tissues
using co-immunoprecipitation.

MPTP treated wild-type mice also had lower
levels of striatal dopamine compared to
vehicle-treated wild-type mice. Dopamine
levels were not significantly different in
vehicle-treated and MPTP-treated Lingo-1
knockout mice.

Reference

There was a higher number of surviving
tyrosine hydroxylase neurons in the 6-OHDA
treated Lingo-1 knockout compared to wildtype mice. There were also increased levels of
the neuroprotective form of Akt (p-Akt) in the
ventral midbrain of the MPTP-treated
knockout compared to wild-type mice.
In the wild-type mice that had received 6OHDA treatment, there was a significantly
higher level of Lingo-1 protein in the striatum
3 days after injury.
Lingo-1-Fc treatment resulted in unilateral
increase in the number of tyrosine
hydroxylase neurons, and in dopamine levels
in the substantia nigra pars compacta.
Lingo-1 decreases EGFR protein levels in a
dose-dependent manner. The anti-Lingo-1
antibody 1A7 blocked the binding of Lingo-1
to EGFR. EGFR activation was suppressed by
Lingo-1, and the 1A7 antibody was able to
attenuate these effects; therefore Lingo-1 can
reduce EGFR levels by direct physical
interaction.
Schizophrenia,
Major
Depressive
Disorder,
Bipolar

BDNF, TrkB, p75

Human post-mortem brains
from schizophrenia, major
depressive disorder and
bipolar disorder subjects

Post-mortem anterior hippocampal and
cerebellum brain samples were obtained from
the Stanley Foundation Neuropathology
Consortium. The cohort consisted of 15
schizophrenia subjects, 15 major depressive

Reductions in BDNF were seen in all layers of
the right but not left hippocampus in major
depressive disorder patients, with no changes
in the dentate gyrus.

Dunham JS. et. al.
2009
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disorder subjects, 15 bipolar disorder subjects
and 13 age and gender matched controls.

A similar but less pronounced pattern was
observed for bipolar disorder.

Protein levels of BDNF, TrkB and p75 were
assessed in the hippocampal samples by
western blotting and immunoautoradiography.

Bipolar, but not major depressive patients had
bilateral reductions in p75 in hippocampal
layers, but not in the dentate gyrus.
No changes in TrkB were seen in any
diagnosis.

Genomic DNA was extracted from the
cerebellum samples from each subject, and
genotyping was performed using the
Sequenom iPLEX platform, for several SNPs
located in the BDNF, NTRK2 and NGFR
genes (full list not disclosed).

Reference

BDNF density was reduced in subjects who
carried the minor allele for rs12273363 and
rs7127505.
TrkB density was decreased in subjects who
carried the minor allele for rs1187323 and
rs1187326.
p75 density was increased in subjects who
carried the minor allele for rs11466117.

Schizophrenia

EGFR

Human post-mortem brains
from schizophrenia subjects

Post-mortem brain samples from the
dorsolateral prefrontal cortex (BA46) were
obtained from 37 schizophrenia subjects and
37 matched controls.
EGFR mRNA expression was assessed by in
situ hybridization and quantitative real-time
PCR.
Protein levels were assessed by western
blotting

Increased EGFR protein was seen in the
dorsolateral prefrontal cortex of schizophrenia
subjects compared to controls.

Swaminathan V.
et. al. 2014

There were no significant differences in
mRNA levels between patients and controls.
Protein levels were significantly correlated
with mRNA levels in both the schizophrenia
group and in the control group.
Subjects with no history of suicidality had
significantly higher levels of EGFR protein
and mRNA compared to those with
suicidality.

Schizophrenia

Lingo-1, NgR, p75,
TROY, WNK1,
Myt1

Human post-mortem brains
from schizophrenia subjects

Post-mortem brain samples from the
dorsolateral prefrontal cortex (BA46) were
obtained from 37 schizophrenia subjects and

Significant increases in Lingo-1 and Myt1
were observed in the DLPFC of schizophrenia
brains compared to controls. Additionally, a

FernandezEnright F. et. al.
2014
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37 matched controls. Samples were taken
from the middle one-third (rostro-caudally) of
the middle frontal gyrus from coronal slabs
anterior to the genu of the corpus callosum.

significant decrease in NgR was observed in
the same region.

Post-mortem brain samples from the
hippocampus (CA1 and CA3 regions), taken
from the level of the lateral geniculate nucleus
were obtained from 20 schizophrenia subjects
and 20 matched controls from the same cohort
as the DLPFC samples.

Schizophrenia

Myt1l

Human, Chinese

Schizophrenia

Myt1l

Human, Caucasian

Both TROY and WNK1 were significantly
increased in the CA1 hippocampal region in
schizophrenia compared to control subjects.
NgR was significantly increased in the CA3 of
schizophrenia subjects compared to controls.
No significant changes in MBP levels were
reported in any brain region.

Protein levels for Lingo-1, NgR, p75, TROY,
WNK1, Myt1 and MBP were assessed by
western blotting in all 3 brain regions.

Confounding factors had no impact on levels
of protein expression.

Genomic DNA samples were collected from
528 paranoid schizophrenia patients (264
males and 264 females (mean age 27.32±8.03
years)) and 528 healthy controls (264 males
and 264 females (mean age 27.73±8.01
years)).

The SNP rs17039584 was significantly
associated with schizophrenia, even after
Bonferroni correction.

Genotyping was performed for 6 SNPs in the
Myt1l gene (rs17039584, rs10190125,
rs17338616, rs10432710, rs6742365,
rs2385135) using the Illumina GoldenGate
assay on a BeadStation 500G Genotyping
System.
A genome-wide screen for copy number
variations was performed on a small cohort of
54 Dutch schizophrenia subjects, using an
Affymetrix GeneChip 250K SNP array.
4 of the novel copy number variations were
chosen based on their gene content for further
validation by multiplex ligation-dependent

Reference

Li W. et. al. 2012

The SNP rs10190125 was found to be
significantly associated with schizophrenia in
female patients.
The SNP rs6742365 was associated with a
family history of schizophrenia in females.

A total of 90 copy number variations were
identified, 77 of which had previously been
reported in unaffected control cohorts.

Vrijenhoek T. et.
al. 2008

13 novel copy number variations were
identified in this study, of which 7 did not
affect any gene, nor were they located in
highly conserved regions.

26

Disease

Protein(s)

Species/Model/Cell Line

Study Details

Findings

probe amplification or genomic quantitative
PCR.

The four copy number variations validated
included 2 duplications in chromosomal
regions 2p25.3 (affecting 4 genes – including
Myt1l) and 5p15.2 (affecting 7 genes), and 2
deletions in chromosomal regions 2p16.3
(affecting the NRXN1 gene) and 9q33.1
(affecting the ASTN2 gene).

The second part of this study involved
studying copy number variations within the 4
loci in a large Dutch case control cohort
consisting of 752 schizophrenia subjects and
706 unaffected controls.

Reference

Within the larger cohort, an additional 8 copy
number variations were identified (7 in
patients and 1 in a control subject). The 4
variations that affect coding sequences were
found only in the patient cohort, including 1
previously unreported copy number variation
at 2p25.3, a 3.8 Mb duplication affecting 11
genes including Myt1l.
Schizophrenia

Myt1

Human post-mortem brains
from schizophrenia subjects

Post-mortem hippocampal and cerebellar
tissue was collected from 44 schizophrenia
patients (29 males and 15 females; of which
24 were African American and 20 were
Caucasian), and 84 normal controls (62 males
and 22 females; of which 53 were African
American, 25 were American Caucasian, 5
were Hispanic and 1 was Asian). Subjects
were matched for age, brain pH and postmortem interval.
Hippocampal Neuregulin1 (NRG1) mRNA
expression was measured by quantitative RTPCR using an ABI Prism 7900 sequence
detection system with 384-well format.
Genomic DNA was extracted from cerebellar
tissue. A total of 10 SNPs within NRG1 were
genotyped; 4 from the de-CODE core
haplotype (SNP8NRG221132,
SNP8NRG221533, SNP8NRG241930 and
SNP8NRG243177) and 6 additional SNPs

NRG1 type I mRNA expression levels were
increased in the hippocampus of schizophrenia
patients compared to controls. No significant
differences were observed for any of the other
NRG1 isoforms.

Law AJ. et. al.
2006

None of the SNPs examined showed any
effect on the expression of type II or type III
NRG1 isoforms.
There was a genotype x diagnosis interaction
for SNP8NRG221132 and type I NRG1
mRNA expression; however there was no
main effect of genotype.
There was a significant main effect of
SNP8NRG243177 on type IV NRG1
expression.
Individuals heterozygous for the (T) risk allele
in SNP8NRG243177 have 21% more type IV
NRG1 mRNA than those individuals
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from HAPMAP (rs10096573, rs4268090,
rs4298458, rs4452759, rs4733263 and
rs4476964). Genotyping was performed using
the TaqMan 5’ exonuclease allelic
discrimination assay.

homozygous for the (C) major allele.

Putative transcription factor binding site
analysis was performed using
MATINSPECTOR software, a computational
suite for promoter informatics.

Reference

Individuals homozygous for the (T) risk allele
in SNP8NRG243177 have 49% more type IV
NRG1 mRNA than those individuals
homozygous for the (C) major allele.
This effect appeared more pronounced in the
schizophrenia group, despite no diagnosis x
genotype interaction being present.
The SNP8NRG243177 was found to be within
a putative binding site for serum response
factor (SRF) and myelin transcription factor 1
(Myt1). Carrying the risk (T) allele results in a
predicted loss of binding to both of these
transcription factors.
The SNP8NRG243177 variant was found to
be within a predicted transcription factor
binding domain for SRF, with the risk (G)
allele abolishing SRF binding.

Schizophrenia

Schizophrenia

NgR

NgR, Nogo-A

Human

Human, mixed ethnicities

A total of 695 patients with schizophrenia,
schizoaffective disorder or schizophreniform
disorder were screened for 22q11 interstitial
deletions.

2 deletions were identified and characterized
by fluorescence in situ hybridization. Both
were hemizygously deleted for cosmids N25
(D22S75) and DO832 (D22S502).

A separate study consisting of 18 velocardial
facial syndrome patients, of which 4 also had
schizophrenia, were screened to test they
hypothesis that a more extensive deletion may
be present in the subgroup of velocardial
facial syndrome patients who also have a
diagnosis of schizophrenia.

No correlation exists between the extent of the
deletion and the additional schizophrenia
phenotype; however the prevalence of
schizophrenia in this small sample (22%) is
much higher than that of the general
population (1%).

The case control cohort for SNP genotyping
consisted of 636 Caucasians (336

rs701428 was found to be weakly associated
with schizophrenia, with the minor allele

Karayiorgou M.
et. al. 1995

Budel S. et. al.
2008
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Cells, E7 chick retinal
explants

schizophrenia and 300 controls) and 296
African Americans (196 schizophrenia and
100 controls). DNA was also obtained from
1122 Chinese Trios (621 schizophrenia
patients and 501 controls).

enriched in the Caucasian group.
4 novel missense variations were identified in
the cohort of 542 schizophrenia probands
(R377W, R377Q, R227C and R399W), with 3
of the 4 novel variants predicted to disrupt
protein function (R377W, R227C and
R399W). While R377Q and R377W are not
within the ligand-binding domain, they are in
the region of the protein that is required for
signal transduction, and may disrupt signaling.

Cells, E13 chick dorsal root
ganglion (DRG) explants
Cells, dissociated E20 rat
DRG cultures
Mouse, NgR knockout

A total of 7 SNPs in the NgR gene (rs701421,
rs701428, rs1567871, rs696880, rs854927,
rs9606296 and rs701427) were genotyped
using a TaqMan SNP Genotyping Assay.
DNA from a separate cohort of 542
schizophrenia probands and NgR variant
pedigrees, along with 650 healthy controls
were obtained for DNA sequencing.
The entire translated region, plus approx. 500
bp of the 5’ and 3’ untranslated region was
sequenced.

Reference

Wild-type NgR sensitizes E7 chick retinal
explants to Nogo-A, whereas the R377Q or
R377W variants do not. Similarly MAGmediated inhibition of neurite outgrowth in
E20 rat DRG neurons is supported by wildtype NgR but not by the NgR R377 variant.

E7 chick retinal explants and E13 chick DRG
cells (expressing wild type NgR or the novel
NgR variants) were used for growth cone
collapse experiments.

E13 chick DRG neurons express NgR and are
responsive to Nogo-A, whereas R377Q and
R377W substituted proteins block the function
of the endogenous NgR and function as
dominant negatives.

E20 rat DRG cultures were used for neurite
outgrowth experiments.

NgR knockout mice have impaired working
memory in the spatial delayed alternation task.

Cognitive assessment in NgR knockout and
wild-type mice was assessed in the spatial
delayed alternation task.

A small subset of NgR knockout mice exhibit
decreased prepulse inhibition.

NgR knockout and wild-type mice also
underwent prepulse inhibition testing.
Schizophrenia

NgR

Human, Caucasian

Genomic DNA from a total of 120 unrelated
schizophrenia patients (77 males and 43
females) and 300 controls (180 males and 120
females) were screened for mutations in the
NgR gene using denaturing high performance

3 mutant alleles were detected in the
schizophrenia patients. 2 were missense
mutations and 1 was a synonymous codon
variant.

Sinibaldi L. et. al.
2004
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liquid chromatography.
All subjects were of Italian origin.

1 patient was heterozygous for a cytosine to
thymine transition resulting in an arginine to
tryptophan substitution (R119W). This
mutation is located in the 3rd leucine-rich
repeat which is expected to be an important
functional domain.

The crystallographic structure of NgR was
used to evaluate the functional relevance of
the R119W and R196H mutations.

Reference

Another patient was heterozygous for a
guanine to adenine transition resulting in an
arginine to histidine substitution (R196H).
This mutation is located in the 6th leucine-rich
repeat.
These change mutations were not found in any
of the 600 control chromosomes.
Both of the missense mutations were predicted
to alter the electrostatic binding properties of
NgR, and may result in alterations in the
function and/or stability of the NgR, possibly
affecting its ability to bind to other
components of the receptor complex (p75 and
Lingo-1).
The patient with R119W mutation suffered
deficit syndrome schizophrenia, while the
patient with R196H suffered early onset and
disorganized schizophrenia. The negative
symptoms of both patients were strongly
resistant to both conventional and novel drug
treatments.
Schizophrenia

WNK1

Human

Microarray technology by Affymetrix was
used to determine the expression of over
30,000 mRNA transcripts in the post-mortem
anterior prefrontal cortex (BA 10) in 28
schizophrenia and 23 control brains collected
from Charing Cross Hospital.

A total of 51 gene expression changes were
common to both groups of schizophrenia
patients, and of these changes, 49 of them
showed the same direction of diseaseassociated regulation.

Maycox PR. et.
al. 2009

WNK1 was shown to be upregulated in both
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The results of this study were then compared
to an independent dataset acquired from the
prefrontal cortex (BA 9) of 16 schizophrenia,
and 27 control brains, collected from the
Harvard Brain Bank.

prefrontal cortical regions of the post-mortem
schizophrenia brain from both the Charing
Cross and the Harvard Brain Bank cohorts.

ELISA competition assay was used to
determine if Lingo-1-Fc can inhibit Lingo-1
binding to NgR.

Lingo-1-Fc significantly decreased the
binding of Lingo-1 to NgR.

Sprague-Dawley rats underwent a lateral
hemisection procedure at cervical vertebra C7,
to completely interrupt the rubrospinal tract
components. Long-1-Fc was administered
locally using a gel foam sponge soaked with
20 μg/10 μL Lingo-1-Fc protein placed at the
site of injury.
Long Evans rats underwent a dorsal
hemisection procedure at thoracic vertebra T7
to completely interrupt the main dorsomedial
and the dorsolateral corticospinal tracts. An
intrathecal catheter was inserted into the
subarachnoid space at T7 and a mini-osmotic
pump delivered Human Lingo-1-Fc fusion
protein (25 μM), Human IgG isotype control
protein (5 mg/mL) or PBS at a rate of 0.25
μL/h.

Reference

Ji B. et. al. 2006

Lingo-1-Fc treatment significantly improved
both forelimb and hindlimb functional
recovery, promoted axonal sprouting and
decreased RhoA activation in both dorsal and
lateral hemisection models.
Lingo-1-Fc treatment also increased
oligodendrocyte and neuronal survival after
either rubrospinal or corticospinal tract
transection.

Functional recovery, RhoA activation and
histological analyses were performed to assess
the effectiveness of the Lingo-1-Fc treatment
following spinal cord injury.
Spinal Cord
Injury

Lingo-1

Rat, Long Evans
Primary cell culture,
cerebellar granular neurons
from P7 rats

Long Evans rats underwent a dorsal
laminectomy procedure at thoracic level T6
and T7. A dorsal hemisection was performed
to completely disrupt the main dorsomedial
and the minor dorsolateral corticospinal tracts.

In situ hybridization and
immunohistochemistry showed that Lingo-1 is
expressed in neurons.

Mi S. et. al. 2004

Lingo-1 mRNA was detected in PN2, PN4
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and PN8 cultured cerebellar granular neurons.

Cells, COS-7

Rats were euthanized and tissues were
collected for Lingo-1 expression analysis.
RT-PCR was used to quantify Lingo-1 mRNA
levels in rat brains and injured spinal cords.
In situ hybridization was used to detect Lingo1 mRNA in rat brain, spinal cord and dorsal
root ganglia.
Primary cerebellar granular neurons were
cultured from P7 rats, and were seeded onto
slides pre-coated with OMgp-Fc, Nogo-66GST, myelin, Lingo-1-Fc, or control-Fc.
Immunohistochemistry was used to detect
levels of Lingo-1, NgR and p75 in rat brain
sections and PN7 rat cerebellar granular
neurons.
A separate lot of cerebellar granular neurons
were transfected with dominant negative
(DN)-Lingo-1, and vector control. DN-Lingo-1
expression in the cells was verified by western
blotting.
COS-7 cells transfected with Lingo-1, NgR
and p75 were immunoprecipitated and
analyzed by western blotting.

Reference

Immunohistochemistry revealed that Lingo-1
expression was higher in the PN7 cerebellar
granular neurons than in the corresponding
adult tissue.
Immunohistochemistry also showed that
Lingo-1 was detected in rat spinal cord axonal
tracts following injury.
Quantitative RT-PCR showed that Lingo-1
was increased 5-fold 14 days following injury.
COS-7 cell culture experiments showed that
Lingo-1 and NgR are able to bind to each
other.
RhoA activation in Lingo-1-, p75-, and NgRtransfected COS-7 cells showed that Lingo-1,
NgR and p75 can together mediate the
inhibitory activities of myelin.
DN-Lingo-1 transfected neurons showed
diminished responses to inhibitory substrates,
evidenced by the presence of longer neurites
than the cells transfected with the control
vector.

COS-7 cells were transfected with NgR and
p75, or with NgR, p75 and Lingo-1, and
analyzed for alkaline phosphatase (AP)OMgp, AP-Nogo or AP-Lingo-1 binding by
ELISA.
GTP-bound and total RhoA proteins were
detected in Lingo-1-, p75-, and NgRtransfected COS-7 cells by western blotting.
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Spinal Cord
Injury

NgR

Mouse, NgR knockout

NgR knockout mice were generated from
C57BL/6J mice.

NgR knockout mice display hypoactivity and
motor impairment.

Kim JE. et. al.
2004

NgR knockout and wild-type mice were
subjected to open field testing for locomotor
activity and rotarod testing for motor
coordination and learning.

DRG neurons lacking NgR do not bind NogoA, and their growth cones are not collapsed by
Nogo-A.

Myelin inhibitory proteins Nogo-A, MAG
OMgp and CNS myelin were examined for
growth cone collapsing activity in wild-type
versus NgR knockout PN14 DRG cultures.
Mice underwent a dorsal laminectomy
procedure at thoracic level T6 and T7. A
dorsal hemisection was performed at T6 to
completely disrupt the dorsal and dorsolateral
corticospinal tracts. Complete transections
were performed at T8.

Recovery of motor function after dorsal
hemisection of the spinal cord is improved in
NgR knockout mice.
Corticospinal fibers do not recover in NgR
knockout mice after hemisection; however
some raphespinal and rubrospinal fibers do
regenerate.

The corticospinal and rubrospinal tracts were
traced with injections of biotin dextran amine
(BDA).
Locomotor recovery in NgR knockout versus
wild-type mice following a midthoracic dorsal
hemisection injury was assessed by open field
testing.
Spinal Cord
Injury

Lingo-1, NgR, p75,
TROY

Mouse, BALB/c

Distribution and intensity of mRNA signal
and immunoreactivity for receptors of myelin
associated inhibitors was assessed by in situ
hybridization for NgR, Lingo-1, p75 and
TROY, and immunohistochemistry for p75.
Neuronal cell groups that project into the
spinal cord and express one or more of the
receptors for myelin inhibition were examined
using co-localization of in situ hybridization

In situ hybridization, immunohistochemistry
and neuronal tracing revealed that NgR and
Lingo-1 are strongly expressed in several
neuronal populations of the adult mouse brain
projecting into the spinal cord, including: the
corticospinal, reticulospinal, raphespinal and
vestibulospinal tracts.

Barrette et. al.
2007

p75 expression was restricted to the neuronal
populations in the descending pathways from
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or immunofluorescence labeling of the
neuronal tracer Fluoro-Gold (FG) injected into
the thoracic spinal cord.

the brainstem. TROY was absent from most
brain regions and from all neuronal projection
systems.

Spinal cord sections were stained with an antiglial fibrillary acid protein (GFAP, a marker
of astrocytes) antibody, Luxol fast blue
(LFB)/cresyl violet (CV) and FluoroJade B
(FJB), to examine the extent of tissue loss and
axonal damage in mice subjected severe spinal
cord contusions.

In the mice that underwent severe spinal cord
contusions, GFAP astrocytes accumulated
around the site of the injury forming a glial
scar. 3D spinal cord reconstructions and
labeling with FJB revealed that axons from
several projection systems were injured.

Reference

Quantitative analysis of in situ hybridization
signals for receptors of myelin associated
inhibitors revealed no significant difference in
average number of positive cells and
hybridization signal per cell between naïve
and spinal cord injury mice. There was also no
change in the expression profile of receptors
for myelin associated inhibitors over time
post-spinal cord injury.
Spinal Cord
Injury

TROY

Chinese Hamster Ovary
(CHO) cells

CHO cells at 90% confluence were transfected
with various combinations of human NgR, rat
p75, and human Lingo-1 constructs.

Cells, COS-7
Mouse, TAJ knockout
Primary cell culture, PN7
cerebellar granular neurons
and dorsal root ganglion
(DRG) neurons from TAJ
knockout mice

ELISA plates coated with soluble NgR were
incubated with serial dilutions of alkaline
phosphatase (AP)-TAJ, AP-p75 or control-AP
to quantify bound AP-TAJ.
COS-7 cells were transfected with
combinations of full-length human TAJ,
human NgR, human Lingo-1 and rat p75.
Western blotting was used to assess levels of
NgR, Lingo-1 and TAJ/TROY.
Quantitative RT-PCR was performed for TAJ,
p75, NgR, and Lingo-1 on whole mouse brain
homogenates taken over a developmental

AP-TAJ was found to bind to cells which
expressed NgR, NgR/Lingo-1 and
NgR/Lingo-1/p75, but not to vector
transfected cells or CHO cells expressing only
p75 or Lingo-1.

Shao et. al. 2007

TAJ binds to NgR and can replace p75 in the
p75/NgR/Lingo-1 complex to activate RhoA
in the presence of myelin inhibitors.
TAJ and p75 showed differential expression
patterns in the rat brain across developmental
time-points, with p75 expression peaking at
E14 and E18 but dropping into adulthood. TAJ
was expressed at its highest between PN0PN8. Higher levels of TAJ were observed in
PN23 and adult samples compared to
expression of p75. Levels of Lingo-1 and NgR
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time-course (embryonic day E14 and E18, and
postnatal day PN0, PN4, PN8, PN23 and adult
brains).

mRNA resembled those of TAJ, with highest
expression being at PN4 and declining slowly
into adulthood.

COS-7 cells were transfected with various
combinations of TAJ, NgR, and Lingo-1. The
cells were subsequently treated with APOMgp, GST-Nogo-66, MAG-Fc or control.
Western blotting was then used to assess for
levels of RhoA in the various cells.

In vitro exogenously added soluble TAJ
reversed neurite outgrowth in normal
cerebellar granular neurons and DRG neurons
caused by myelin-associated inhibitor factors
MAG, OMgp and Nogo.

Cerebellar granular neurons and DRG neurons
from TAJ knockout mice were assessed for
neurite outgrowth in vitro.
Stress and
Depression

Akt, BDNF, TrkB

Rat, Sprague-Dawley
Mouse, C57BL/6
Mouse, CD1 retired breeders
Human, post-mortem brains
from depressed subjects

Chronic fluoxetine was administered via
subcutaneous implants of pellets in the dorsal
interscapular region. The pellets delivered 20
mg/kg/day of fluoxetine or placebo over a 20day interval.
C57BL/6 mice were subjected to a social
defeat paradigm using resident CD1 mice as
the aggressors.
Samples from post-mortem human ventral
tegmental area and both the ventral tegmental
area and nucleus accumbens from the
C57BL/6 mice were used in western blotting
assays for Akt, phospho-Akt, BDNF, and
TrkB.

Traumatic Brain
Injury

MAG

Rat, Sprague-Dawley

Adult male rats were subjected to either lateral
fluid percussion brain injury or sham injury.
Treatment with either 8.64 μg anti-MAG
monoclonal antibody or IgG control antibody,
delivered by osmotic minipumps, began 1

Reference

Neurons from TAJ knockout mice were more
resistant to the suppressive action of the
myelin inhibitors.

Susceptibility to social defeat was associated
with a significant reduction in levels of
active/phosphorylated Akt within the ventral
tegmental area.

Krishnan V. et. al.
2008

Chronic antidepressant treatment in both mice
and humans resulted in increased active Akt
levels.
Defeat induced reduction in Akt activation in
susceptible mice was necessary and sufficient
to induce depressive behaviors associated with
susceptibility.
Pharmacological reductions in Akt resulted in
a significant rise in the firing frequency of
ventral tegmental area dopamine neurons.
At 72 hours post-injury, rats showed increased
immunoreactivity for MAG in the ipsilateral
cortex, thalamus and hippocampus of brain
injured animals; anti-MAG was detected in
the hippocampus, fimbria and ventricles.

Thompson HJ. et.
al. 2006
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hour post injury and continued for 72 hours.

Brain-injured rats that received anti-MAG
antibody treatment showed significantly
improved recovery of sensorimotor function at
6 and 8 weeks post-injury compared to the
brain-injured IgG control treated rats.

One group of rats was euthanized at the 72
hour post injury time-point to verify drug
diffusion and MAG immunohistochemistry.
All other rats were evaluated for up to 8 weeks
post-injury to assess neurologic motor,
sensory and cognitive function using a battery
of previously described tests, including but not
limited to the rotarod test, adhesive paper test,
and Morris water maze test.

Reference

8 weeks post-injury, anti-MAG treated braininjured rats showed significantly improved
cognitive function and reduced hemispheric
tissue loss compared to brain-injured controls.

Hemispheric tissue loss was evaluated at 8
weeks post-injury.
Traumatic Brain
Injury and
Epilepsy

RhoA

Rat, Sprague-Dawley

Male rats were subjected to a lateral fluid
percussion brain injury; cortex and
hippocampus from both hemispheres were
collected 24 h to 3 days after injury.
A second set of male rats were administered
kainic acid (10 mg/kg i.p.) to induce seizure;
brains were collected 24 h after injections and
bilateral hippocampi were removed.
GTP-RhoA pull down assays were performed
on rat cortical and hippocampal tissue
homogenates.

Traumatic Brain
Injury

RhoA

Human, post-mortem brains
from traumatic brain injury
subjects

The post-mortem cohort consisted of brains
from 25 patients who died after various
survival times following closed traumatic
brain injury, in addition to 4 brains of
neuropathologically normal cases used as
controls.
Immunohistochemistry was used to detect
RhoA expression throughout the brain at

RhoA activation was increased from 24 h to 3
days post-injury in the cortex, and by 3 days
in the hippocampus, ipsilateral to the injury.

Dubreuil CI. et.
al. 2006

RhoA activation was also detected in the
cortex and hippocampus contralateral to the
injury, without alterations in the level of
RhoA.
Severe seizures resulted in bilateral RhoA
activation in cortex and hippocampus.

The main cellular sources of RhoA after
traumatic brain injury were
monocytes/macrophages, granulocytes and
neurons.

Barabeck C. et. al.
2004

Following closed traumatic brain injury there
was a significant increase in the number of
parenchymal cells expressing RhoA at the
lesion site, but not in neighboring areas.
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There were no significant differences in the
number of RhoA positive cells in the very
early stages following injury (<7 hours);
RhoA expression was confined to shrunken
eosinophilic neurons.
RhoA expression was highest between 1-2
weeks post injury and was predominantly
expressed in macrophages at this stage postinjury.
In the later stages post-injury (months),
additional staining was observed in reactive
astrocytes.

Tuberous
Sclerosis &
Cortical
Dysplasia

Nogo-A

Human, surgical specimens
from pediatric patients
undergoing surgery for
epilepsy.

Brain biopsy specimens were used to examine
the expression patterns of the Nogo-A system
in cortical lesions of 28 pediatric patients with
tuberous sclerosis complex (TSC) (n=16) and
focal cortical dysplasia type IIb (FCDIIb)
(n=12). Control white matter cortical
specimens were obtained from the brains of 10
normal-appearing brains of pediatric patients
without a history of seizures or other
neurological disorders at autopsy.
Western blotting and immunohistochemistry
were used to examine expression levels of
Nogo-A, NgR, Lingo-1, TROY, p75 and
RhoA in the brain specimens of FCDIIb, TSC
and control subjects.

mRNA and protein levels of Nogo-A, NgR,
Lingo-1, TROY and RhoA, but not p75 were
upregulated in the cortices of patients
compared to autopsy controls.

Yu S-X. et. al.
2012

Immunohistochemistry showed that Nogo-A
and NgR were expressed strongly in
misshapen cells, particularly in dysmorphic
neurons, balloon cells and giant cells.
TROY was diffusely expressed in the
malformations of cortical development.
The majority of Nogo-A/NgR positive cells
were co-labeled with neuronal rather than
astrocytic markers.

Quantitative RT-PCR was used to examine
relative levels of Nogo-A and NgR mRNA in
all samples.
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Abbreviations: 6-OHDA: 6- hydroxydopamine; ADI-R: Autism Diagnostic Interview-Revised; Akt: protein kinase B; AP: alkaline phosphatase; APP: amyloid precursor
protein; ASTN2: astrotactin 2; BA: Brodmann’s Area; BDA: biotin dextran amine; BDNF: brain derived neurotrophic receptor; CA1: Cornu Ammonis 1; CA2: Cornu
Ammonis 2; CA3: Cornu Ammonis 3; CA4: Cornu Ammonis 4; CHO: Chinese Hamster Ovary; CNPase: 2',3'-Cyclic-nucleotide 3'-phosphodiesterase; CNS: central nervous
system; CSPG: chondroitin sulfate proteoglycan; CV: cresyl violet; DN: dominant-negative; DRG: dorsal root ganglion; E: embryonic day; EAE: myelin oligodendrocyte
glycoprotein-induced experimental autoimmune encephalomyelitis; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; ELISA: enzyme linked
immunosorbent assay; ErbB2: receptor tyrosine-protein kinase erbB-2; Fc: fragment crystallizable; FCDIIb: focal cortical dysplasia type IIb; FG: Fluoro-Gold neuronal
tracer; FJB: FluoroJade B; FL: full-length; GFAP: glial fibrillary acidic protein; GST: glutathione S-transferase; HA: hemagglutinin; HB-EGF: heparin-binding epidermal
growth factor-like growth factor; HEK: human embryonic kidney; i.p. intraperitoneal; LFB: luxol fast blue; Lingo-1: leucine-rich repeat and Ig domain-containing, nogo
receptor-interacting protein; LPC: lysophosphatidylcholine; LRR: leucine-rich repeats; LV/Lingo-1-shRNA: lentiviral vectors encoding Lingo-1 short hairpin RNA; mAb:
monoclonal antibody; MAG: myelin associated glycoprotein; Mb: mega base pairs; mceph/mceph: BALB/cByJ-Kv1.1mceph/mceph mice; miRNA: microRNA; MPTP: N-methyl4-phenyl-1,2,3,6-tetrahydropyridine; mRNA: messenger RNA; mTOR: mammalian target of rapamycin; Myt1: myelin transcription factor 1; Myt1l: myelin transcription
factor 1-like; NgR: nogo receptor; Nogo-A: neurite outgrowth inhibitor; NRG1: neuregulin1; NRXN1: neurexin-1-alpha; OMgp: oligodendrocyte-myelin glycoprotein; OPC:
oligodendrocyte precursor cell; p75: p75 neurotrophin receptor; PCR: polymerase chain reaction; Phospho: phosphorylated; PI3-K: phosphatidylinositide 3-kinase; PN:
postnatal day; RGC: retinal ganglion cell; RhoA: ras homolog gene family, member A; RNAi: RNA interference; RT-PCR: real-time polymerase chain reaction; SHR:
spontaneously hypertensive rats; SNP: single nucleotide polymorphism; SRF: serum response factor; TAJ: TNF receptor orphan Y (TROY); tcTPC: time-controlled
transcardiac perfusion cross-linking; TNFRSF19: Tumor necrosis factor receptor superfamily, member 19 (TROY); TrkB: tropomyosin receptor kinase B; TROY: TNF
receptor orphan Y; TSC: tuberous sclerosis complex; VPA: Valproic acid; WNK1: WNK lysine deficient protein kinase 1; WOD: weighted ocular dominance.
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